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Cyclosporine is used in veterinary medicine to treat a number of inflammatory
and immune-mediated conditions, however firm oral dosing protocols have yet to be
established in the dog. Traditionally a pharmacokinetic approach, through measurement
of blood drug concentrations, has been the primary method of establishing if the given
dose is effectively suppressing the immune system. However, there is some debate over
how well blood drug concentrations correspond to immunosuppression, since individuals
can vary in response to the same drug concentration. Our research group believes that a
pharmacodynamic approach could alternatively be used to accurately determine
cyclosporine dosages in individual patients since this will give a measurement of the
immune system’s response to the drug, rather than simply how the body is processing it.
This method will give a more accurate assessment of the patient’s immune system, and
allow for better immunosuppressant therapy. The objective of this thesis was to develop a
quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay that could
reliably predict patient outcome during cyclosporine treatment. This assay would
essentially work as a diagnostic tool that clinicians can use to help determine if they were

using an appropriate cyclosporine dose for their patients. The assay measures cytokine
expression of activated T cells, which are the target cell for the active metabolite of
cyclosporine. Our objectives were achieved, firstly, through validation of the assay. Since
this assay will be used by clinicians throughout the nation, we first established if shipping
conditions affected the sample, and therefore assay results. Once the effect of sample
storage time and temperature were determined, optimal sample collection timing was
established. Finally, cytokine levels were measured in samples from clinical cases and
healthy control dogs to examine the difference in cytokine expression between these two
groups. An effective and reliable treatment method for cyclosporine has yet to be
established in the dog; therefore the results of this thesis will lead to better therapeutic
monitoring and more efficient use of cyclosporine therapy in canine patients.
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LITERATURE REVIEW
The immune system is essential for the body to function properly and provides
protection against disease. Both innate and adaptive immunity defend the body against
pathogens like viruses, parasites, and bacteria. This system is like a double-edged sword,
and if not tightly regulated, can become wildly destructive. Regulation is accomplished
through a number of cell mediators and immune cell interactions, but when these
components are able to escape tight regulation, autoimmune disease results. The
pathogenesis of autoimmune diseases can be incredibly complex, involving both genetic
and environmental factors, and these diseases can therefore often times be very difficult
to treat. This is especially true in veterinary medicine, since most therapies have been
developed for use in humans, and are not thoroughly evaluated in companion animal
species. Thus the focus of this thesis is to develop a better understanding of the treatment
of immune-mediated disease in canine patients, with a specific emphasis on the
immunosuppressive drug cyclosporine.
Cyclosporine
Cyclosporine A (CsA) is a powerful immunosuppressive agent used in both
human and veterinary medicine to prevent transplant rejection and to treat a variety of
inflammatory and immune-mediated diseases. Its discovery provided a major
breakthrough for transplant medicine, and it is still widely used today. Cyclosporine use
1

is also growing in the veterinary medical field, as it is employed to treat an increasing
number of inflammatory and immune-based diseases.
Discovery and Synthesis
Cyclosporine was first discovered in the 1970s at the Sandoz Lab located in
Switzerland, and involved the efforts of both F. Borel and H. Stӓhelin.1 In 1958 the
Sandoz company set up a screening system for antibiotics. At that time employees would
regularly pick up random soil samples while traveling or on vacation, and bring back the
samples to the laboratory for testing on the slight chance that they would contain a
microorganism that could be developed into the next great antibiotic.2 While on holiday
in Norway, H.P. Frey picked up a soil sample intending to return it to the laboratory for
testing, completely unaware that he held the key to the drug that would revolutionize
transplant medicine.2 In the meantime, another laboratory was being set up in the Sandoz
company that experimented on immunosuppressive properties of test compounds under
Drs. H. Stӓhelin and S. Lazary.1 Frey’s sample, number 24-556, was submitted to both
the general screening program, as well as to Stӓhelin’s laboratory for immunosuppressive
testing after extraction.1 Stӓhelin tested the extract on mice, observing its cytostatic
activity and lack of cytotoxicity, and found significant immunosuppressive effects, while
Borel performed a hemagglutinin test using mouse serum.2 A second sample of 24-556
was submitted to Borel’s laboratory, but upon testing produced disappointing results
compared to the previous study. Despite its poor performance, however, the group
decided to continue investigation into the compound.1
The original soil sample contained the saprophyte Tolypocladium inflatum, a
pathogen of beetle larvae that produces many secondary metabolites with potential uses
2

within the medical and agricultural industries, including cyclosporine.3 Borel
characterized many of the immunosuppressive properties of cyclosporine in mice via skin
and bone marrow transplantation studies. In these experiments, Borel showed that
cyclosporine inhibits lymphocyte proliferation, suppresses cellular and humoral
immunity, and has low myelotoxicity.4 After Borel presented his findings at the British
Society for Immunology in London in 1976, other laboratories began experimenting with
the cyclosporine molecule in other animal species and humans, with exciting results.1
Based on these experiments, researchers recommended clinical investigation of
cyclosporine’s potential for use in transplant therapy, but first absorption, distribution,
and metabolism in healthy individuals needed to assessed.5 There were a few issues
initially with absorption in humans due to the lipophilic nature of cyclosporine, however
once the correct vehicle was used, the problem resolved.5
In the late 70s, the first clinical investigations of cyclosporine in human patients
began. In a study of 34 patients with organ allografts, the majority of organs were still
viable, some after more than a year, using cyclosporine as an immunosuppressive agent.6
Further studies confirmed that an ideal protocol would combine cyclosporine and
glucocorticoids to maximize immunosuppression, while minimizing cyclosporine’s toxic
effects on the kidney, and avoiding infection.5,7 In 1983 the FDA approved the use of
cyclosporine for preventing organ rejection after transplantation in people.8
Cyclosporine is a cyclic polypeptide whose chemical structure was revealed using
a combination of x-ray crystallography and chemical degradation.9 After the usefulness
of cyclosporine was determined in clinical trials, it was important to develop a method of
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synthesizing the drug in mass quantities. Not only would this make the drug more widely
available, but also it would cheapen its cost.
Cyclosporine Formulations
There are two distinct formulations available for oral cyclosporine in the dog.
Sandimmune®, the original preparation, is a corn-oil based drug first introduced to the
market in the 1980s. While considered the gold standard to prevent organ rejection in
transplant medicine at the time, it displayed significant variation between patients in
terms of absorption and oral bioavailability.10-12 This led to the production of a new
ultramicronized formulation named Neoral®. This product formed a microemulsion with
gastrointestinal fluids after oral consumption, which evenly distributed the drug
throughout the fluid, allowing better absorption.13 Studies showed this new formulation
displayed lower inter- and intra-individual variability, and achieved more predictable
blood drug concentrations.11,14 In 2003 the FDA approved a veterinary microemulsion
formulation (Atopica®) for use in dogs. Since its approval, Atopica® has undergone
multiple pharmacokinetic studies in dogs, and thus is the recommended formulation for
use in canine patients.
Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion
Once ingested, cyclosporine is transported to, and then absorbed by, the epithelial
cells of the small intestine. Cyclosporine is not well absorbed orally, and its
bioavailability can differ greatly from one individual to the next. In dogs, bioavailability
can range from 23% to as much as 45% and, in the presence of food, can be further
reduced by 20%.15 Diabetes, gastric motility issues, diarrhea, and liver disease can also
4

impact absorbability.10,16 P-glycoprotein pumps within the intestinal cells can also
diminish CsA levels by pumping the drug from the enterocyte cytoplasm back into the
intestinal tract, although so far this has been shown to only be an issue in man and not
dogs.17,18
After intestinal absorption, CsA enters the bloodstream, circulating throughout the
body. Its high lipid solubility allows it to easily cross cell membranes.10 The drug prefers
red blood cells (RBCs) over plasma proteins at a ratio of 2:1.10 While in the plasma
,cyclosporine is 80-90% protein bound, mostly to high density lipoprotein, and it
typically distributes within RBCs; therefore a patient’s RBC count and lipoprotein
numbers can impact drug distribution.10,16 Post-circulation, cyclosporine accumulates in
the skin, liver, kidneys and fat, and will maintain sustained drug levels in these sites even
after discontinuation of therapy.10,19
Metabolism of cyclosporine occurs mainly in the liver by way of the cytochrome
P450 system, which alters CsA into a number of metabolites through hydroxylation or Ndemethylation.20 The rate of metabolization differs from species to species, but in the dog
70-100% of the drug is metabolized in the first 30 minutes.20 The main cytochrome P450
enzymes responsible for cyclosporine metabolism are CYP3A4 and CYP3A5.16 The
predominant metabolites in the dog, in decreasing order of quantity, include 9 γhydroxylated metabolite, 4 N-desmethylated metabolite, 1-β-(8΄) hydroxylated
metabolite, and 1-β-1-ε-cyclized metabolite.20 Total quantities of individual metabolites
are known to vary from one species to another, with baboons and hamsters having the
most comparable numbers to humans.20 A number of factors can impact CsA metabolism,
including liver disease, age, and other drugs.10 Several drugs are known to inhibit CsA
5

metabolism, and one is often used purposefully to decrease oral doses while maintaining
adequate blood levels. Ketoconazole tends to be the drug of choice for generating this
effect in dogs, and works by inhibiting cytochrome P450. Ketoconazole has been shown
to reduce CsA doses by as much as 75%, which can greatly reduce the cost of treatment
for owners.21
The majority of cyclosporine metabolites are excreted through the bile, with an
elimination half life time of about 9-12 hours in the dog.15 Only a very small percentage
of the drug’s metabolites are excreted in the urine, and therefore kidney disease does not
greatly impact drug excretion.10,16,20
Mechanism of Action
After the discovery of its immunosuppressive properties, much work went into
unraveling cyclosporine’s mechanism of action. Cyclosporine is a potent inhibitor of T
lymphocytes. During a normal immune response, antigens are presented to T cell
receptors. This binding results in a signaling cascade within the cell, leading to cytokine
production, cell proliferation, and an overall enhancement of the immune response. T
cells play a vital role in cell-mediated immunity, and are important for destroying
infected and tumor cells,22,23 maintaining immunological tolerance,22,23 providing an
immune memory response,24 and assisting other white blood cells (WBCs) during an
immune response.25 It is essential for T cells to function properly because, when they
become hyperactive, immune-mediated disease results, while reduced T cell function can
lead to immune deficiencies and infection. Disease states resulting from overactive T
cells are often treated using immunosuppressive agents like cyclosporine, which targets
the abnormal immune cell response.
6

Cyclosporine works predominantly by inhibiting the activity of T lymphocytes.
When an antigen complexed with the major histocompatibility complex (MHC) binds to
a T cell receptor (TCR), a signaling cascade results. This binding results in a
conformational change, making the receptor’s immune receptor tyrosine activation motifs
(ITAM) sequences, which reside in the cell cytoplasm, more accessible. This action
recruits the tyrosine kinase Lck (lymphocyte-specific protein tyrosine kinase), which
phosphorylates the ITAMs, thus activating them. Another cytosolic tyrosine kinase,
ZAP70 (zeta-chain associated protein kinase 70 kDa) is also activated by Lck. ZAP70s
phosphorylation results in the recruitment and activation of other proteins, including
SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa). SLP-76 binds
phospholipase C, which then cleaves PIP2 (phosphatidylinositol biphosphate) into two
substrates, DAG (diacylglycerol) and IP3 (inositol triphosphate). Within the cytosol, IP3
binds to the endoplasmic reticulum, causing the release of calcium into the cell interior.
The influx of calcium causes activation of the calcium-dependent intermediate messenger
calmodulin, which subsequently binds and activates calcineurin, which is usually found
in the cytosol of the cell. Activated calcineurin dephosphorylates regulatory sites on the
transcription factor nuclear factor of activated lymphocytes (NFAT). NFAT then
translocates to nucleus and induces transcription of certain cytokines including
interleukin-4 (IL-4), tumor necrosis factor- α (TNF-α), interferon-γ (IFN-γ), and IL-2.26
Cyclosporine works by interfering with the T cell activation signaling cascade at
the level of calcineurin. When cyclosporine enters the cell, it binds to the cytosolic
protein cyclophilin, specifically cyclophilin A, since this is the main type of cyclophilin
found in T cells. This complex of cyclosporine and cyclophilin inhibits calcineurin,
7

which normally activates NFAT. Since NFAT is thereby not dephosphorylated, and
therefore does not localize to the nucleus, the resulting effect is decreased expression of
cytokines controlled by NFAT. This leads to inhibition of proliferation and activation of
both helper and cytotoxic T lymphocytes, and an overall decrease in the immune
response.
Adverse Reactions
Cyclosporine has a relatively narrow therapeutic window, and has mostly
concentration-dependent side effects. Side effects tend to be more common at higher
doses, and are usually reversed once the drug is discontinued.19 Gastrointestinal
symptoms are the most common adverse reactions, and include vomiting, diarrhea,
nausea, and decreased appetite. These can sometimes occur even at the low dosage used
to treat atopic dermatitis in dogs.19 Other reported side effects in dogs include gingival
hyperplasia, excess shedding, papillomatosis, and hypertrichosis.15 Although kidney
function may be impaired in human patients receiving cyclosporine, this issue is not
commonly reported in the veterinary literature. One study, using beagle dogs, kept them
on a very high 45 mg/kg daily dosage for 12 months, and observed no change in the
nephrotoxicity biomarker calbindin.27 It is still not understood why dogs seem to be
protected from nephrotoxicity due to cyclosporine, since humans and rats can undergo
renal damage at much lower doses.
Cyclosporine should be used carefully in the presence of other drugs, since it is
known to have reactions with some of them. Doxycycline, methylprednisolone,
erythromycin, and grapefruit juice have all been shown to increase cyclosporine blood
levels, while omeprazole and rifampicin are known to decrease them in humans.19 In the
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veterinary field azole antifungals such as ketoconazole, calcium channel blockers, and
macrolide antibiotics are just some of the drugs known to increase blood levels when
used in combination with cyclosporine.15
Contraindications for cyclosporine use include a previous diagnosis of malignant
neoplasia in dogs, and uncontrolled infection or hypertension in man, since suppressing
the immune system can worsen diseases of this nature.15,19 Cyclosporine is known to
increase production of transforming growth factor- beta (TGF-β) and vascular endothelial
growth factor (VEGF), cytokines which are known to enhance tumor growth.28
Cyclosporine also inhibits DNA repair, and has anti-apoptotic properties.28 The
combination of all of these effects can theoretically lead to cancer and encourage
metastasis if neoplasia is already present. Cyclosporine can cause hypertension in man,
however the exact mechanism is still not well understood. It is hypothesized that
increased prostaglandin production and decreased excretion of sodium, water, and
potassium contribute to hypertension.29,30 Cyclosporine should also be used
conservatively in veterinary patients suffering from renal or hepatic disease.
Cyclosporine is able to cross the placental barrier, as well as enter the milk of lactating
individuals, therefore it should not be used in pregnant or nursing patients.19
Pharmacokinetic Monitoring
Monitoring cyclosporine drug therapy is essential for a number of reasons: there
is wide individual variability in CsA pharmacokinetics, a threshold drug concentration
must be reached to minimize the risk of treatment failure, and toxicity must be avoided
by ensuring trough concentrations are not over a safe limit.10 Studies describing
monitoring of CsA concentrations have been undertaken using a variety of blood sample
9

types as well as a number of different analysis techniques, and because of these variations
it is often difficult to compare studies.
Blood, plasma, and serum have all been used as potential sample types for
monitoring CsA concentrations. Whole blood drug levels seem to give the most
consistent numbers compared to serum or plasma.10 Easier sample collection as well as
the ability to store heparinized samples before running the assay make the use of whole
blood more convenient than plasma or serum.10
Radioimmunoassay (RIA) and high performance liquid chromatography (HPLC)
are the two most widely studied methods for measuring CsA concentrations. RIA is an
extremely sensitive procedure which measures CsA concentrations through the use of
radiolabeled drug and binding site competition principles.31 There are a couple of issues
with using RIA, however. Samples outside the range of the linear curve have been
observed in patients with liver problems, leading to the need for sample dilution, and
results in these patients can be misleading since ideally an undiluted sample should be
used.10 Furthermore, RIA is not very specific, since a number of CsA metabolites can
cross-react during analysis. Cross-reactivity ranges anywhere from 4-32% depending on
the metabolite in question, meaning that samples can be given a falsely high drug
concentration, since not all metabolites actively suppress the immune system.10
Cyclosporine concentrations measured by RIA have been found to be consistently higher
compared to HPLC measured samples, likely due to CsA metabolites.31 A number of
CsA metabolites have little or no immunosuppressive properties, therefore a falsely high
reading can make it appear that the patient is sufficiently immunosuppressed when, in
reality, they require a higher dose.10 HPLC is a more labor intensive method and requires
10

specialized equipment and experienced users, which are not available at all facilities. For
HPLC, a series of columns and solvents are used to separate the sample into its
component parts, allowing one to measure drug concentrations. This makes the method
more specific than RIA, since there is no metabolite cross reaction.10 HPLC is therefore
the gold standard for measuring CSA blood concentrations, especially in patients with
liver issues, since there is no metabolite cross reactivity.
More recently, liquid chromatography-mass spectroscopy (LC-MS) has been used
to measure CsA concentrations.32-35 One study even validated an assay that could be used
in dried blood spots, allowing patients the convenience of taking blood samples at
home.33 While this technique is used in human patients and in research, it has yet to be
validated for use in canine patients.
Once sample type and analysis method were perfected, the next step was to
identify when to take the sample post-dosing. Initially, monitoring trough concentrations
was suggested to avoid over dosage and potential liver and kidney damage. Trough
samples would be taken just before the next dose of CsA was given, representing the
lowest drug concentration achieved. There was much debate in transplantation medicine
over ideal blood trough concentrations, with recommended target concentrations ranging
anywhere from 100-500 ng/ml ,depending on the institution and the assay used.36 Wide
ranges in suggested target trough blood concentrations and poor correlation to clinical
outcome lead scientists to search for a better marker of immunosuppression and toxicity.
Kahan suggested using the area under the concentration-time kinetic curve, originally
starting with a 12 hour time window.37 This method, however, was quite impractical for
use in patients, given the number of samples and processing time needed. Shorter time
11

frames were therefore investigated for area under the curve measurement. A 4 hour
sampling technique proved useful,38 however sample collection and preparation was still
labor intensive, and the search for a better test still continued. Eventually, peak drug
concentrations (2 hour post-dose sample) were found to correspond well with the risk of
graft rejection.39 Studies in man show that peak drug concentrations are reached 2 hours
after oral dosing, and thus this is the recommended time for blood collection for
therapeutic monitoring.40,41 Similar sample collection times have been established in the
dog as well.42 A recent study in our own laboratory showed peak cyclosporine
concentrations were reached 2 hours after drug administration, then fell rapidly thereafter
to trough levels.43 Measurement of a single peak drug concentration is much more
convenient than measuring area under the curve, and provides physicians with a method
for individualizing therapy that allows for CsA’s wide inter-individual variability.
A similar search for ideal cyclosporine monitoring techniques has been embarked
upon in veterinary medicine. Cyclosporine is used to treat a number of immune-mediated
diseases in dogs, therefore having a monitoring protocol in place would be ideal, since
CsA pharmacokinetics has been shown to be variable between individual canine patients.
However, little work has been done in this area, and current blood concentration
recommendations are mostly extrapolated from studies of kidney transplantations in
dogs. As in human medicine, initial attempts to monitor CsA in dogs began using trough
concentrations. The starting recommendation was to obtain a trough drug concentration
of 500-600 ng/ml.44 Veterinary medicine has mirrored its human counterpart, and now
reference laboratories often recommend monitoring both trough and peak samples,
although target peak levels have yet to be thoroughly evaluated in the dog. Target values
12

also vary depending on the laboratory and analysis method used. A new and more
efficient test that reliably predicts clinical outcome would be highly beneficial for
veterinary patients receiving CsA, since some of the diseases that this drug is used to treat
are life threatening, sometimes necessitating rapid changes in dosing regimens in order to
save the patient.
Pharmacodynamic Monitoring
While measuring blood cyclosporine concentrations was originally the primary
means of assessing immunosuppression in patients, individuals vary widely in response
to the same dose, and published target blood concentrations vary from one institution to
the next. Dogs may even vary in immune response to the same cyclosporine blood
concentration; therefore even though a patient may have achieved a therapeutic blood
concentration according to certain standards, sufficient immunosuppression may not be
reached due to individual variation in response to the drug. One way to address this
problem is to take a pharmacodynamic approach to measuring cyclosporine’s effect on
the immune system, rather than solely a pharmacokinetic one. By measuring the drug’s
impact on the immune system, rather than merely how the body is processing the drug by
measuring blood concentrations alone, immunosuppressive effects can be more reliably
evaluated, and dosages can be better tailored to the individual patient. Such
pharmacodynamic monitoring has already been successfully employed in human
transplant medicine. Similar to pharmacokinetic monitoring, a number of different
techniques, including quantitative reverse transcription polymerase chain reaction (qRTPCR),45,46 T cell proliferation assays,47 calcineurin inhibition48 and flow cytometry,49,50
have all been explored as potential new assays. While pharmacodynamic monitoring
13

offers a great opportunity for individualizing drug therapy, a number of issues still need
to be perfected, such as which biomarkers to test and how to assess them.
A number of studies have evaluated T cell production of cytokines, primarily IL-2
and INF-γ, in response to drug therapy, as a pharmacodynamic biomarker assay of
cyclosporine’s effects. IL-2 is mainly produced by activated T cells, and promotes B and
T cell proliferation and differentiation.51 IL-2 is known to be inhibited by exposure to
cyclosporine both in vitro and in vivo, and this response has been studied in mice,52
humans,52,53 and dogs.54 Minimal or no inhibition of IL-2 production has been correlated
to acute organ rejection in transplant recipients receiving cyclosporine, and patients with
high IL-2 levels prior to transplantation were more likely to reject the new organ.50,55
Similar IL-2 levels were found between stable graft patients and healthy volunteers,
while levels were higher in patients suffering acute rejection episodes.56 IL-2 receptor
expression has also been evaluated, and some studies have shown an increased number of
IL-2 receptors in patients with cyclosporine-induced nephrotoxicity, and during rejection
episodes.56 However, cyclosporine does not directly influence IL-2 receptor expression,
and measuring T cell cytokine production has been shown to be a more sensitive
indicator of rejection.56 Like IL-2, INF-γ is produced by T cells, but is mainly responsible
for macrophage activation.57 T cell INF-γ production is also used as a biomarker of
cyclosporine therapy, and INF-γ has shown to decrease in expression with drug therapy,
although this result has been variable between studies.56 It has therefore been suggested
that measurement of INF-γ may not be specific enough for evaluating cyclosporine
therapy.56 Other cytokines that have been investigated as potential biomarkers for
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cyclosporine therapy include IL-4, IL-6, TNF-α, granulocyte macrophage colonystimulating factor (GM-CSF), and IL-4.
Initial pharmacokinetic monitoring of blood drug concentrations was cumbersome
and time-consuming, and therefore alternative methods of measuring cyclosporine’s
effect were explored. In 1998 van den Berg et al. developed a flow cytometry-based
clinical assay to monitor the immunosuppressive effect of drugs in human transplant
recipients.58 The assay measured the functional effect of cyclosporine via
intracytoplasmic IL-2 production. A negative correlation was found between IL-2
production and cyclosporine blood concentration, suggesting that the test could be used
to assess cyclosporine’s cellular effects. A later study in lung transplant recipients
showed similar results, and the authors suggested that this technique would be more
useful than monitoring blood drug concentrations, and could be used to better tailor
immunosuppressive therapy to the individual patient.59 Similar protocols have been
explored in the canine patient, although this type of assay has yet to be offered as a send
out test for general practitioners using immunosuppressive agents.43,54,60 While flow
cytometric assays have the capacity to detect specific cell populations and therefore are
more specific for T cell function, samples must be processed the same day of collection,
which can be challenging to accomplish if multiple samples are received throughout a
working day. Another limitation to flow cytometry is that it involves a time-consuming
protocol which, once started, must be completed the same day. Unfortunately flow
cytometry is impractical for use in a clinical setting in which samples may get submitted
at inconvenient times.
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Quantitative reverse-transcriptase PCR (qRT-PCR) has also been explored for its
potential use in pharmacodynamic monitoring of immunosuppressants. In 1993 Koutouby
et al. developed a qRT-PCR based assay that, like flow cytometry assays, measured
cyclosporine’s effect via IL-2 expression.61 The protocol utilized peripheral blood
mononuclear cells, and found decreasing levels of IL-2 transcription with increasing
levels of cyclosporine in vitro. While this technique does not directly measure the amount
of IL-2 protein produced, mRNA levels are known to correlate to protein expression
levels.62,63 Although use of qRT-PCR can allow for samples to be stored post RNA
collection, Koutouby’s protocol took 24 hours to complete and therefore could not be
efficiently used in a clinical setting. More recent advances in qRT-PCR made the
technique faster, and protocols using whole blood sample were established, which
shortened sample processing. Like flow cytometry, qRT-PCR has also been previously
tested in dogs. One in vitro study showed that canine mononuclear cells had a
concentration-dependent reduction in IL-2, IL-4, and IFN-γ mRNA expression when
incubated with cyclosporine.64 Another group demonstrated increased IL-2 and IFN- γ
expression levels in tissue biopsies from dogs suffering from anal furunculosis.65 Tissue
IL-2 levels then dropped significantly after the initiation of cyclosporine therapy, the
recommended treatment protocol for anal furunculosis.
Another approach to the pharmacodynamic monitoring of cyclosporine is to
measure calcineurin enzyme activity. Calcineurin is an intracellular phosphatase that is
inhibited by the CsA-cyclophilin complex in a concentration-dependent manner.66 This
inhibitory effect has been observed in whole blood, leukocytes, and peripheral blood
mononuclear cells,67-69 although whole blood samples are reported to be superior to the
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others.67 A number of assays have been developed, each of which has a different
approach to quantifying calcineurin activity. Koefoed-Nielsen et al. developed an assay
that estimates calcineurin activity by measuring its ability to dephosphorylate a
radioactive peptide via liquid scintillation. Dealing with radioactive substances proved to
be challenging, however, so more rapid and feasible methods were explored. Sellar et al.
developed a spectrophotometric-based detection method, and although the convenience
of whole blood sampling is lost, the protocol can be completed in one workday using
standard laboratory equipment.68
Although a number of pharmacodynamic assays have been validated for use in
human patients receiving cyclosporine, few such assays exist for veterinary patients, and
most veterinarians rely on the measurement of blood drug concentrations to assess CsA
efficacy. Lymphocyte proliferation70 and qRT-PCR cytokine quantification64 have been
evaluated in dogs on topical or systemic cyclosporine, but as of yet no one has validated
these assays for use in canine clinic patients receiving immunosuppressive doses of
cyclosporine. As has been observed in humans, dogs have variable responses to
cyclosporine therapy; therefore an assay that can accurately assess the drug’s effect on
the immune system would be helpful in tailoring immunosuppression therapy.
Immune-Mediated Diseases
Autoimmune diseases are the result of dysregulation of the body’s immune
system. This immune system is normally under tight regulation through a system of
checks and balances involving a number of different cell types and inflammatory
mediators. Dysregulation can occur as a result of a genetic predisposition, certain
environmental factors, or both. A number of autoimmune diseases have been described in
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veterinary medicine, and those in which cyclosporine is a recommended therapy will be
further discussed, including immune-mediated hemolytic anemia (IMHA), immunemediated thrombocytopenia (IMT), inflammatory bowel disease (IBD), atopic dermatitis,
and anal furunculosis (AF).
Immune-Mediated Hemolytic Anemia (IMHA)
Immune-mediated hemolytic anemia (IMHA) is a type II hypersensitivity reaction
and, in dogs, is one of the more common diseases of the immune system.71,72 IMHA is
characterized by antibody-mediated destruction of red blood cells, leading to all of the
symptoms associated with anemia. The disease was first described in dogs in the 1960s73
and, since then, much has been discovered concerning its etiology, clinical signs,
diagnosis, and treatment. Yet despite our increased understanding of the condition, and
the development of numerous therapeutic options, many patients with IMHA still have a
relatively poor outcome.71,72,74
In the healthy animal, aged or damaged red blood cells are filtered out of the
blood by the mononuclear phagocyte system (MPS).71 The MPS contains both
macrophages and monocytes dispersed in the blood and throughout tissues in the body,
including the spleen, central nervous system, lymph nodes, and liver.57 One of the
functions of the MPS is to clear aging RBCs from the blood, which is accomplished by
antibodies targeted to antigens present on the RBC membrane.71 When a RBC reaches the
end of its lifespan, its membrane becomes more rigid and fragile and eventually becomes
coated with antibody.75 The RBC is then targeted for ingestion by a macrophage either in
circulation or in one of the organs of the MPS.75 After ingestion by a macrophage, the
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RBC is then broken down by lysosomal enzymes, so that iron and other cell components
can be recycled by the body.75
In a dog suffering from IMHA, antibodies produced by the humoral immune
system bind to antigens on RBCs of all ages, thereby targeting them for premature
destruction by macrophages and, in some cases, also resulting in the activation of the
complement cascade.71,76 In some patients, RBC precursor cells of the bone marrow can
be targeted for destruction as well.71 Without an adequate number of functioning RBCs,
oxygen cannot be adequately distributed throughout the body. RBC shortage has an
impact on all of the body’s systems, since oxygen is essential for every cell to function.
One of the most common targets of anti-RBC autoantibodies is glycophorin, a
transmembrane glycoprotein found on RBCs.71 Antibodies can be of the IgG, IgM, or
IgA isotype, and the specific isotype has been shown to be correlated to disease
severity.71 Since the IgM isotype is better at fixing complement, diseases associated with
IgM tend to be more severe.71
There are two main types of IMHA, primary and secondary. In the more common
primary or idiopathic IMHA, there is no underlying cause for the disorder.71 Antibodies
produced by the body target antigens on the RBC membrane. Secondary IMHA, in
contrast, often results from an acquired immune response to a foreign antigen that is
linked with a RBC membrane. Secondary IMHA can be caused by a variety of
conditions, including infection, neoplastic disorders, and even the use of certain drugs.71
Infections from viruses, bacteria, and protozoa have all been found to be associated with
IMHA.71 There is also thought to be an association between IMHA and vaccination, but
a specific vaccine has yet to be identified, and the exact mechanism by which vaccination
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causes IMHA has yet to be established.71 There are also a few different forms of IMHA
including peracute IMHA, acute IMHA, chronic IMHA, cold agglutinating IMHA, and
pure red cell aplasia.77 Acute IMHA is the most common form seen in dogs, while the
chronic form tends to develop more in cats.77
Dogs of any age can develop IMHA, but typically symptoms emerge after the first
year of life.72,74 Usually anemia develops fairly quickly, and most dogs act lethargic, lose
their appetite, and occasionally experience vomiting and diarrhea.72 Upon physical
examination, signs can include pale mucous membranes, jaundice, an enlarged spleen and
liver, pigmented urine, fever, rapid breathing, and swollen lymph nodes.71
Certain breeds such as cocker spaniels, toy and miniature poodles, and old
English sheepdogs are more susceptible to developing IMHA, suggesting a possible
genetic component to the disease.78 One of the main events in the development of the
disease is when the MHC proteins recognize self or foreign proteins, therefore genes
coding for MHC molecules are thought to be possible candidates for genetic
predisposition to IMHA.72 Females and castrated males have a higher frequency of
IMHA72,79 with the majority of cases occurring in middle-aged female dogs.71
Correct diagnosis of IMHA is essential for appropriate treatment, since a different
therapeutic approach is taken depending on whether the patient is suffering from the
primary or secondary type. The underlying cause needs to be addressed in secondary
IMHA, while treatment for primary IMHA involves aggressive immunosuppressant
therapy.71 Typical hallmarks of IMHA include a positive Coomb’s test, autoagglutination, and spherocytosis.77 To diagnose primary IMHA, slide agglutination or a
direct Coomb’s test are usually the first tools used, and show if anti-erythrocyte
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antibodies are present.72 Other diagnostic techniques for anti-RBC antibodies include
flow cytometry, enzyme-linked immunosorbent assays, and a gel test.72 With flow
cytometry, one is able to detect and quantify IgG and IgM antibodies bound to RBCs.77
A variety of treatment options are available for patients diagnosed with IMHA,
ranging from surgery (splenectomy) to immunosuppressant drug use. The ultimate goals
of most therapies are to suppress antibody production and/or RBC lysis and
opsonization.76,80 Glucocorticoids are often the first drug of choice for IMHA treatment,
in order to induce remission of the disease.76 Prednisone, prednisolone and
dexamethasone are the most common glucocorticoids used. Glucocorticoid mechanism of
action includes suppression of the transcription of a number of pro-inflammatory
cytokines, which helps to reduce the activity of macrophage RBC opsonization as well as
the complement system.76 Glucocorticoids also inhibit Fc (fragment crystallizable)
receptors on the macrophage membrane, preventing the receptors from binding and
opsonizing antibody-coated RBCs.76 While glucocorticoids are often effective for
inducing remission in IMHA patients, they are not ideal for long-term use to maintain
remission due to the numerous side effects associated with their use.76
Once remission of IMHA has been induced, an immunosuppressant drug is
usually prescribed to maintain remission and avoid relapse.76 In severe cases,
immunosuppressive agents can also be used during initial therapy. A number of agents
have been used in IMHA treatment, including azathioprine, mycophenolate mofetil
(MMF), leflunomide, and cyclosporine, each of which has a slightly different mechanism
of action with their own advantages and disadvantages. Azathioprine inhibits purine
synthesis, ultimately inhibiting cell activation and proliferation.15 MMF also inhibits
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purine synthesis via the de novo pathway, resulting in the suppression of T and B cell
activity.15 Leflunomide targets T cells by inhibiting pyrimidine synthesis and decreasing
DNA and RNA synthesis.15 Cyclosporine, as described previously, suppresses T cell
NFAT-regulated cytokine production via inhibition of calcineurin.55 Azathioprine and
cyclosporine are the immunosuppressive agents most commonly used to treat canine
IMHA.71
Human intravenous immunoglobulin (hIVIG) has also been used to treat IMHA.
Like glucocorticoids, hIVIG works by reducing macrophage phagocytosis as well as
complement activation.76 HIVIG is typically used to treat severe cases of IMHA, given
its rapid onset and effectiveness.76
When a dog is suffering from severe IMHA, and is not responding well to
immunosuppressive therapy, another option to consider is splenectomy.76 The spleen is
responsible for filtering the blood, but also functions as a site for antibody production,
and as a key organ in the MPS system that phagocytoses RBCs. Since the spleen is not
essential for survival, splenectomy is a feasible option to induce and maintain IMHA
remission.76 However, in dogs in which IMHA is mediated by IgM autoantibodies, it less
likely to be effective.76
Even though there are a number of therapeutic options available to treat IMHA
patients, the survival rate is still relatively poor, with only 50% of patients surviving.71
Most patients that do not survive die within the first two weeks after diagnosis.72 Usually
death results from hypercoagulable blood resulting in pulmonary thromboembolism or
disseminated intravascular coagulation.71 However, dogs that survive this initial phase
typically have a good outcome in the long run.76 While our understanding of IMHA has
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improved and a number of treatment options have been developed, new therapies that
target severe cases and more research is needed to improve patient survival.
Immune Mediated Thrombocytopenia (IMT)
Immune-mediated thrombocytopenia, often also referred to as idiopathic
thrombocytopenic purpura (ITP), is an autoimmune disorder in which the body’s defense
system produces antibodies against platelet antigens, targeting platelets for destruction.
This leads to a low platelet count, predisposing to excessive bleeding and, ultimately,
death if not properly treated. IMT can be idiopathic,81 or it can be triggered by a number
of factors including parasites82, neoplasia83, bacterial or viral infection84, or
medications.85 In idiopathic or primary IMT, disease begins with the attachment of
autoantibodies to platelet surface antigens, or deposition of immune complexes on the
platelet exterior.86 In particular, the surface antigens GP (glycoprotein) IIb /IIIa or Ib/IX
complexes have been found to be targets for autoantibodies in the dog.87,88 T cells are
largely responsible for ensuring the immune system doesn’t attack self cells, and some
studies have found either abnormal numbers or function of T cells in patients with
IMT.89-91 Gender, genetics, and environmental factors can all contribute to the
pathogenesis of the disease.92 Once bound by autoantibodies, the platelets are then
targeted for destruction by macrophages in organs such as the spleen. The macrophages
recognize the Fc receptor of the antibody bound to the platelet, and then destroy the
platelet via phagocytosis.
IMT can be diagnosed in dogs of any age, but the condition has a predilection for
females and certain breeds, including cocker spaniels, poodles, German shepherds and
old English sheepdogs.92 Typical presenting patient complaints include mucosal and
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cutaneous hemorrhage, lethargy, reduced appetite, bloody diarrhea, and bruising.92
Diagnosis involves attaining an accurate platelet count and blood smear evaluation.
Antiplatelet autoantibody assays have been developed for the dog and can help facilitate
a diagnosis. These assays can either detect antibodies in the serum that have the ability to
bind platelets, or antibodies directly bound to the platelet surface. Assays for plateletbound antibody are done via flow cytometry and have a high sensitivity, although they
are prone to false positive results.92,93 While a number of tests are available to aid in the
diagnosis of IMT, typically it is a diagnosis of exclusion after ruling out all other possible
causes of thrombocytopenia.
A number of therapeutic options are available to treat IMT. Glucocorticoids are
the mainstay of most therapeutic regimens. Recovery is primarily due to inhibition of
antibody-induced phagocytosis by macrophages.94 Glucocorticoids specifically work by
impairing Fc gamma receptor function, which leads to reduced binding of IgG coated
platelets and reduced platelet destruction.94 In dogs that don’t respond well to steroid
therapy, additional immunosuppressive drugs are then added. Medications can include
vincristine, cyclophosphamide, azathioprine, MMF, danazol, cyclosporine, and hIVIG.
Vincristine has been shown to be very efficacious in the treatment of IMT. Vincristine
not only increases platelet numbers through stimulation of megakaryocyte breakdown,
but also reduces platelet phagocytosis.92,95 Splenectomy is another therapeutic option.
During treatment, supportive care is very important and while, transfusions are not
commonly required, in the event of uncontrolled hemorrhage, transfusion may be
necessary.92 The goal of treatment is to maintain a normal platelet count within the range
of 60,000-200,000 platelets/µl after removal of all drugs.92
24

Atopic Dermatitis
Canine atopic dermatitis has been diagnosed since the early 1930s.96 Atopic
dermatitis is a type I hypersensitivity reaction involving IgE or IgG antibody.77 While
atopic dermatitis was first thought to be the result of inhaled allergens, years of research
has shown it to be a complex, multifactorial disease in which genetic predisposition and
IgE antibodies generated against environmental antigens are typical.96 Approximately
10% of dogs are affected, with certain breeds such as Chinese Shar-Peis, Boxers,
Dalmatians, Boston terriers, Labrador retrievers, and golden retrievers most commonly
diagnosed.77
Although atopic dermatitis has been around for quite some time, it wasn’t until
recently that a wide scale study on its diagnosis was published.97 Pruritus is the classical
sign of atopy, typically affecting the ears, feet, face, or ventral abdomen,77 although its
presentation can differ depending on breed.96 Pathogenesis involves a number of immune
cells, with mast cells playing a key role. When exposed to an allergen, IgE binding to Fc
receptors on mast cells leads to the release of preformed mediators such as histamine and
cytokines, initiating an inflammatory response.57 Mast cells tend to congregate in the skin
around ears and paws, therefore it’s no coincidence that these sites are the most
commonly affected.96 Increased numbers of both T helper and T cytotoxic cells have
been found in atopic skin lesions.98 Eventually the region is infiltrated by lymphocytes,
dominated primarily by TH1 cells, with progression to chronic inflammation.96 IFN-γ, the
predominant TH1 cytokine, has been shown to be increased in these lesions.99 Given the
role that T cells play in the pathogenesis of atopic dermatitis, therapies targeting this
component of the immune system, such as cyclosporine, should be relatively effective in
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its treatment. The skin barrier itself is also an important component of the pathogenesis of
the disease. In the normal healthy dog, the stratum corneum layer of the skin acts as a
barrier against environmental allergens and transepidermal water loss. Studies have
shown that atopic dogs have lower ceramide and epidermal lipid production100,101,
increased transepidermal water loss100, and decreased filaggrin (a protein that plays a
pivotal role in skin keratinization) production102. All of these contribute to reduced
barrier function of the skin, allowing allergens to penetrate and generate an inflammatory
response.
Diagnosis of atopic dermatitis is largely based on history and clinical signs and,
like IMT and IMHA, atopy is also a diagnosis of exclusion.96 Atopic dermatitis has a
fairly high prevalence within the canine community, with approximately 10% of dogs
suffering from the disease.103 In his 2010 paper, Favrot listed certain criteria that should
be met for a diagnosis of atopy, such as clinical signs that begin to occur before the dog
reaches 3 years of age, pruritus that responds to glucocorticoids, involvement of feet and
ears, and pruritus that occurs before the onset of skin lesions.97 While these criteria can
aid in the diagnosis, they are not all inclusive. Given the fact that certain breeds are more
commonly affected than others, a genetic component to the disease is highly likely.
Microarray analysis has shown differential gene expression in healthy dogs versus dogs
with atopy, particularly those involved in skin barrier function, immune response, gene
transcription, and programmed cell death.104 Allergen testing is also an important
component of diagnosis. Identifying potential allergens and subsequent avoidance can be
quite helpful in controlling the disease in the long run.
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Canine atopy is a lifelong disease, and typically requires lifelong treatment. The
first line of defense is to determine the causative agent for flare ups, and to avoid future
interaction.105 Acute flare ups of atopic dermatitis are typically initially treated with
topical glucocorticoids like hydrocortisone, or oral glucocorticoids.105 Additional
immunosuppressive agents like tacrolimus or cyclosporine are indicated in more chronic
cases.105 Cyclosporine was first approved for use in canine atopic dermatitis in 2002, and
has been shown to be quite effective.106-110 Other potential therapeutic options include
oclacitinib maleate, interferons, commercial canine atopy diets, and antihistamines.111
Anal Furunculosis (AF)
Anal furunculosis (AF) is a disease characterized by chronic inflammatory and
ulcerative lesions forming around the anus of the dog. Dogs suffering from the disease
typically display difficulty defecating, painful ulceration around the anus, purulent sinus
tracts, and reduced appetite.77 Older dogs and those with a broad-based tail are at a
greater risk of developing AF.77 Anal furunculosis is similar to perianal Crohn’s disease
in man, and primarily affects German shepherds.112 Other breeds that have been
diagnosed with AF include Irish setters, Labrador retrievers, Old English sheepdogs, Jack
Russell terriers, border collies, and English bulldogs, as well as various mixed
breeds.113,114
In one study consisting of over 300 dogs, approximately 80% of AF cases were
German shepherds,113 which highly suggests a genetic component to the disease. Much
work has gone into investigating potential genes involved in the pathogenesis of AF. Due
to the fact that T cell specific cytokines have been shown to be increased in AF lesions115
and the fact that the disease is highly responsive to the immunosuppressive agent
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cyclosporine, its highly likely that the immune system plays a role in the pathogenesis of
AF, especially CD4+ T cells.116 T cells are activated once presented with antigen
complexed with MHC class II. Investigations into the link between canine MHC genes
and AF have found there to be a five-fold greater risk of developing AF in German
shepherds carrying the DLA-DRB1*00101 allele.116 However this allele is present in
other breeds, and therefore cannot solely explain the development of disease.116 In
addition to MHC genes, researchers have also looked into pattern recognition receptors
(PRRs), particularly toll-like receptors, of German shepherds, and their potential link to
AF. Although multiple single nucleotide polymorphisms (SNPs) were found, the
researchers concluded that PRRs are not implicated in AF pathogenesis.117 Work
regarding matrix metalloproteinase (MMP) expression has found there to be increased
levels of MMP-9 and MMP-13 in AF lesions, implicating macrophages in its
pathology.118 Macrophage activity has been hypothesized to be due to IFN-γ production
from T helper cells.118 Expression of IFN-γ and IL-2 expression, both of which are
primarily TH1 cytokines, is known to be increased in AF lesions.115 Although cytokine
expression does not correlate with lesion severity, IL-2 has been shown to decrease with
the use of cyclosporine.65 In addition to the immune system genetic susceptibility of
German shepherds, an anatomical predisposition has also been linked to AF. Budberg et
al. found an increased density of apocrine sweat glands in dogs predisposed to developing
AF.119 While an immune component of the disease has been established, the pathogenesis
of the AF likely involves multiple genes as well as an environmental component. The
pathogenesis of AF is still not completely understood and much work still needs to be
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done to have a better understanding of disease development, however investigation into
its treatment appears to be much more productive.
Prior to the use of cyclosporine, AF management was frustrating and difficult for
practitioners, and often included the use of surgery to either remove affected tissue or
amputate the tail.77 While there is evidence suggesting the beneficial use of
immunosuppressive doses of prednisone,120 cyclosporine appears to be the superior
treatment. Cyclosporine has been shown to be very effective in treating AF.114,121-123
Cyclosporine inhibits the activity of T helper cells, without affecting T suppressor cell
function, reducing inflammation and allowing lesions to heal.124 The cost of cyclosporine
often inhibits its long-term use in patients, however using it in combination with
ketoconazole slows its metabolism and prolongs its duration of effect, ultimately leading
to lower costs for the owner and making its use a more feasible option.114 Other
immunosuppressive agents, such as tacrolimus and azathioprine, have also been shown to
be effective therapeutic options for AF.125,126
Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) consists of a group of gastrointestinal diseases
categorized based on location in the body and principal cell type.77 Dogs are mainly
affected by lymphocytic-plasmocytic enteritis (LPE), lymphocytic-plasmocytic colitis
(LPC), and eosinophilic gastroenteritis (EGE) types, named according to predominant
cell types.127 There are also a number of specific IBD forms that commonly occur in
certain breeds, like Boxers, Basenjis, Norwegian Lundehunds, Irish Setters and softcoated Wheaten terriers. The entire gastrointestinal tract can be affected, but the proximal
small intestine is the most commonly affected site in dogs.128 While the cause of IBD is
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unknown, a number of predisposing factors can help initiate or exacerbate disease, such
as genetics, environment, infectious agents, parasites, dietary allergens, and drug-induced
disease. Loss of mucosal tolerance to endogenous bacteria is known to be a crucial factor
leading to the development of chronic inflammation in the gastrointestinal tract.128
Studies with mice and humans have shown that problems with either the mucosal barrier,
mucosal immune system, or endogenous microflora can lead to chronic stimulation of the
immune system, ultimately leading to pathologic change and disease.128 There is likely a
similar pathogenesis in dogs.
Diagnosis of IBD can be a difficult undertaking, since one must rule out all other
potential causes of the gastrointestinal symptoms, however a number of tools are
available to diagnose and monitor IBD. Definitive diagnosis requires biopsy of the
intestinal tract with a histological diagnosis provided by a pathologist. While in human
medicine the most commonly used technique for monitoring is clinical scoring indices,129
specifically the Crohn disease activity index,130 in canine patients veterinarians most
commonly use subjective assessment of clinical signs to determine treatment course
efectiveness.131 To date, two scoring indices have been developed to help manage canine
IBD patients, the clinical IBD activity index (CIBDAI) and the canine chronic
enteropathy clinical activity index (CCECAI). The CIBDAI evaluates six separate
gastrointestinal signs including attitude/activity, appetite, vomiting, stool consistency,
stool frequency, and weight loss. Each is scored on a range of 0-3, and then added
together to give a final score. which is then used to classify the disease based on
severity.132 The CCECAI assesses serum albumin, ascites, peripheral edema, and
pruritus, in addition to the previously mentioned signs, again scoring them from 0-3.133
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This scoring system has shown to be useful in predicting negative outcome.133 While
these scoring systems have their use, most of the parameters are subjectively evaluated,
and are therefore prone to certain errors. Abdominal ultrasound has been studied for IBD
diagnosis, but in dogs evaluating intestinal wall thickness does not appear to be a useful
management tool.131 In human patients, a number of serological markers have been
studied and proven useful in IBD management, therefore clinicians have searched for
similar markers in canine patients. Some of the markers currently under investigation
include C-reactive protein, albumin, cobalamin, folate, and perinuclear antineutrophilic
cytoplasmic antibodies.131 C-reactive protein (CRP) is an acute phase protein synthesized
by the liver, and plasma levels of CRP are increased during inflammation. Measurement
of CRP can be quite informative in human patients, since levels have been shown to be
associated with disease activity, histologic inflammation, and even therapeutic
efficacy.134-137 Serum CRP levels have been shown to be increased in dogs with
IBD,132,138 but one study did not find a correlation between CRP levels and disease
severity or histopathologic grade.138 Although CRP increases in response to any
inflammation and is not specifically associated with the gastrointestinal tract, measuring
CRP can be useful in gauging response to therapy after an IBD diagnosis has been
made.131 Albumin can also be a useful diagnostic marker in IBD cases. Measurement of
albumin is best used as a predictor of negative outcome, since dogs with a severe form of
the disease will tend to lose protein through the gut.133 While biomarkers of IBD have
their use, none stand alone to establish an accurate diagnosis. Biomarkers are mainly
helpful indicators of prognosis or treatment effectiveness.
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The gold standard for IBD diagnosis still continues to be intestinal biopsy
histopathology, collected via endoscopy or laparotomy, to determine degree and type of
inflammation.139 Although collection of biopsies can be an invasive and expensive
procedure, histopathology is useful in determining degree of inflammation and
predominant cell type, which aids in the diagnosis and development of treatment plans.
While endoscopy and histopathology has been the gold standard for a number of years, it
wasn’t until recently that a set of standards on morphologic change and inflammation
evaluation was published. Again, a scoring system is used, which then correlates to
severity of pathologic change in the sample.140 However, to date, this scoring system has
not been validated, and a couple of studies have shown that histopathologic improvement
does not always correlate with clinical improvement.133,141
A number of treatment options are available for IBD, and like the previously
discussed diseases, clinicians usually begin with the use of glucocorticoids, progressing
to other immunosuppressive agents as severity of the disease increases. In addition to
pharmacologic manipulation, dietary changes, antibiotics and probiotics are also added to
the treatment regime. In mild to moderate cases of IBD, dietary modification may be the
only change needed, since the reaction may be due to antigens in the food.142 However,
this is more commonly the case in cats rather than dogs.143 Suggested diets typically
contain a single protein source, and carbohydrates and proteins that the animal has not yet
been exposed to.143 The addition of omega fatty acids can help to alleviate intestinal
inflammation, and use of glutamine will aid in maintaining villous integrity.143 If dietary
change alone is not effective, the addition of probiotics may provide some benefit, but
again the combination of glucocorticoids and probiotics is only recommended for milder
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cases. Probiotics alter inflammatory cytokine production,144 reduce pathogen growth
through production of antimicrobial metabolites,145,146 and stimulate phagocyte
activity.145 Another option is to use an immunomodulatory agent, with β-glucans being
the agent most commonly used.143 β-glucans are a component of the cell wall of most
fungal species and, in IBD cases, they function by acting as antigens, which stimulates
both an innate and adaptive immune response, eventually leading to its suppression.147
However, this type of therapy should only be reserved for milder cases, since human
studies have shown gastrointestinal disease to worsen with the use β-glucans in more
severe cases.143 Topical nonsteroidal anti-inflammatory drugs (NSAIDs) like
sulfasalazine are sometimes used in IBD cases restricted to the large intestine. Other
NSAIDs that can also be used include olsalazine and mesalamine.77 These agents act as
an anti-inflammatory drugs through the suppression of inflammatory cytokines,
prostaglandins, and leukotrienes, and are helpful for treating mild to moderate cases.143
While the previously mentioned therapies have their uses, the most effective
treatment for IBD is immunosuppressive drug therapy. Glucocorticoids are the most
common agent used for both large and small intestine IBD cases.77 Prednisolone is the
drug most often chosen by practitioners, and treatment is usually long-term.143 When
glucocorticoids fail or the side effects become too much to handle, the next step is often
addition of another immunosuppressive agent, such as azathioprine, chlorambucil, or
cyclosporine. In humans, cyclosporine is used in steroid-refractory cases of Crohn’s
disease as a last resort before colectomy, and functions by regulating pro-inflammatory
cytokine production.148 Cyclosporine probably works similarly in canine IBD patients.
One study in IBD dogs treated with cyclosporine found significant improvement in
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clinical signs, reduced clinical activity score, and reduced T cell populations in intestinal
biopsies, and concluded that cyclosporine is an effective treatment for steroid refractory
cases.149 Since it is not advisable for patients to be on immunosuppressants for life,
especially high doses that may be associated with significant side effects, once disease
remission has been maintained for a certain period of time tapering of drug therapy is
recommended. However, if a relapse occurs, immunosuppressant therapy should be
immediately reinstated until clinical signs are under control.143 Although a number of
options are available for treatment of IBD, the overarching goal of any therapy is to
decrease gastrointestinal signs and inflammation, and to promote weight gain as well as a
healthy appetite.
Project Summary
Cyclosporine is used in veterinary medicine to treat an increasing number of
immune-mediated conditions, although the only disease cyclosporine is currently
approved for is atopic dermatitis in dogs and cats. Despite its widespread use, firm oral
dosing protocols have yet to be established in the dog for the range of other diseases that
the drug is used to treat, such as IMHA, IMT, IBD, and anal furunculosis. Currently, a
pharmacokinetic assay is the primary laboratory means of assessing cyclosporine
efficacy, through measurement of blood drug concentrations. The blood drug
concentration is assumed to correlate to level of immunosuppression, however there is
considerable debate regarding this assumption, given that individuals can vary in
response to the same drug concentration. Our research group believes that, by taking a
pharmacodynamic approach to monitoring the effect of cyclosporine on the immune
system, we can better measure the drug’s impact, and develop more individualized drug
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regimens. Using this approach, the immune system’s response to the drug will be
measured, rather than how the body is processing the drug. To address this issue, our
laboratory has evaluated the immunosuppressive effects of CsA on its target T cells, and
has developed a pharmacodynamic qRT-PCR based assay for use in dogs that allows
adjustment of drug dosage based on immunosuppressive effect.
Our laboratory has done some previous work in this field, which set the
foundation for the development of our current assay. Our initial study looked at activated
T cell expression of a number of cytokines, including IL-2, IFN- γ, and IL-4, using flow
cytometry.54 Peripheral blood mononuclear cells (PBMC) were incubated with
cyclosporine, and a decrease in cytokine expression in a concentration- and timedependent manner was observed. Surface markers CD25 and CD95 were also evaluated,
and were also suppressed with the addition of cyclosporine. Next, an in vivo study was
performed in healthy Walker hounds given a high and low dose of cyclosporine.150 The
same cytokines were studied via flow cytometry. Similar results to the previous study
were found for IL-2 and IFN-γ, but not IL-4. These results suggested that IL-2 and IFN-γ
could be used as potential biomarkers for monitoring cyclosporine’s effectiveness. There
was also some preliminary work done using qRT-PCR instead of flow cytometry, which
showed the two assays to be comparable methods for measuring the effects of
cyclosporine on T cells.
The overarching goal of our research was to develop a diagnostic tool that can
reliably predict outcome when a canine patient is on a cyclosporine treatment regime.
Clinicians would then be able to use the assay to allow more efficient and effective
treatment of canine patients. The main objective for this thesis was to develop and
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evaluate a robust qRT-PCR assay that could be used to accurately assess cyclosporine’s
effect on the canine immune system. We hypothesized that T cell cytokine production
would be a reflection of the immunosuppressive effects of cyclosporine, and that
measurement of cytokine expression could be used to determine the effectiveness of
cyclosporine therapy. To address this, we first validated a qRT-PCR assay for measuring
activated T cell cytokine production, specifically IL-2 and IFN-γ, for use in dogs. Next,
the assay was tested with clinical patients with conditions such as IMHA, IMT, IBD,
atopic dermatitis and anal furunculosis, in order to establish pre-treatment cytokine levels
and the ideal timing of sample collection post drug therapy. The project concluded with
an evaluation of the relationship between IL-2 and IFN-γ expression and clinical
outcome, in order to determine how well the assay works in a clinical context.
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Abstract
Cyclosporine is an immunosuppressive agent that inhibits T-cell function by
decreasing production of cytokines such as interleukin-2 (IL-2) and interferon-γ (IFN-γ).
In dogs, there is currently no reliable analytical method for determining effective
cyclosporine dosages in individual patients. Our laboratory has developed a quantitative
reverse transcriptase-polymerase chain reaction (RT-qPCR) assay that measures IL-2 and
IFN-γ gene expression, with the goal of quantifying immunosuppression in dogs treated
with cyclosporine. This study focuses on analytical validation of our assay, and on the
effects of sample storage conditions on cyclosporine-exposed samples. Blood from
healthy dogs was exposed to a typical post-treatment blood concentration of cyclosporine
(500 ng/ml) for 1 hour, and then stored for 0, 24, and 48 hours at both room temperature
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and 4°C. The study was then repeated using a cyclosporine concentration of 75 ng/ml,
with sample storage for 0, 24, and 48 hours at 4°C. Cytokine gene expression was
measured using RT-qPCR, and assay efficiency and inter- and intra-assay variability
were determined. Storage for up to 48 hours did not significantly alter results compared
to samples that were processed immediately. Validation studies showed our assay to be
highly efficient and reproducible and robust enough to be feasible under standard practice
submission conditions.
Introduction
Normal T-cell function is essential for destruction of diseased cells, maintenance
of immunological tolerance, provision of an immune memory response and facilitation of
the involvement of other white blood cells in immune responses.1-4 Immunomodulators,
including immunosuppressive agents, can be used to target T-cells and thereby modify
both cell-mediated and humoral immune responses.
Cyclosporine is an effective immunosuppressive agent used in both human and
veterinary medicine to prevent transplant rejection and treat inflammatory and immunemediated diseases such as atopy, inflammatory bowel disease, immune-mediated
hemolytic anemia, and anal furunculosis.5-8 Cyclosporine is a potent T-cell inhibitor that
works by binding to intracellular cyclophilin, resulting in a cyclosporine-cyclophilin
complex that inhibits calcineurin. Calcineurin is required by the T-cell to produce
nuclear factor of activated T-cells (NFAT)-regulated cytokines, such as IL-2 and IFN-γ,
that help activate T-cells and stimulate lymphocyte proliferation and differentiation.9 The
presence of cyclosporine within the T-cell serves to suppress cytokine production and
ultimately T-cell function.10-12
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An ideal cyclosporine dosing protocol has not been established in the dog. While
measurement of blood cyclosporine concentrations is the standard method of monitoring
therapy, published target blood concentrations vary widely from one reference laboratory
to the next. Individual dogs may even vary in immune response to the same blood
cyclosporine concentration.10 Pharmacodynamic assessment of the actual biological
effects of cyclosporine on T-cell function would be preferable to simple monitoring of
blood drug concentrations, but a clinically validated tool to assess cyclosporine
pharmacodynamics in the dog has not been established. As an important step towards
development of a suitable pharmacodynamic assay, we evaluated a RT-qPCR assay of
NFAT-regulated cytokine gene expression. Our objectives were to perform analytical
validation of the assay using established MIQE (minimum information for publication of
quantitative real-time PCR experiments) guidelines,28 and to determine the effects of
sample storage conditions on cyclosporine-exposed samples when blood was incubated
with cyclosporine at concentrations comparable to levels that are therapeutically feasible
in dogs at standard dose rates.
Materials and Methods
Blood Sample Collection and Storage Study
Two different concentrations of cyclosporine were evaluated in our study. We
initially evaluated the effects of duration of storage at two different storage temperatures
on assay results in samples from 10 dogs when samples were exposed to a concentration
of cyclosporine that is considered to be therapeutic (500 ng/mL). In a subsequent smaller
study, we evaluated the effects of storage duration at a single storage temperature on
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assay results in samples from four dogs when samples were exposed to a concentration of
cyclosporine that is considered to be subtherapeutic (75 ng/mL).
Ten healthy intact female Walker hounds were used. In our initial study, 30 mL of
blood was collected from the jugular vein using a Vacutainer collection system and then
fractionated in 10 aliquots of 3 mL using heparinized tubes. Five of the 3 mL samples of
whole blood were then exposed to cyclosporine at a concentration of 500 ng/mL (Sigma,
St. Louis, MO, USA Cat no. C1832). One sample was processed via addition of
activators (PMA, ionomycin) immediately post-collection and after 1 hour of
cyclosporine exposure, while additional tubes (4) were stored at room temperature or 4°C
for either 24 or 48 hours prior to activation. As a control, 5 untreated (no cyclosporine
addition) samples were included, with one sample processed via addition of activators
immediately post-collection, and the 4 additional tubes stored at the same time and
temperature combinations as the cyclosporine-treated samples.
A subsequent smaller storage study was then completed using a lower drug
concentration and a single storage temperature. Twenty milliliters of blood was collected
from the jugular vein from four healthy intact female Walker hounds. Blood was then
fractionated into six aliquots of 3 mL using heparinized tubes. Half of the 3 mL samples
of whole blood were then exposed to cyclosporine at a concentration of 75 ng/mL
(Sigma, St. Louis, MO, USA Cat no. C1832). After a 1 hour incubation period, one
sample was processed via addition of activators immediately, while additional tubes were
stored at 4°C for either 24 or 48 hours prior to activation. As a control, an untreated
sample was included at all time points.
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T-cell Activation
Whole blood samples were activated using a combination of PMA (12.5 ng/mL)
(Sigma, St.Louis, MO, USA Cat no. P8139-1MG ) and ionomycin (0.8 µM) (Sigma, St.
Louis, MO, USA Cat no. I0634-1MG). Samples were then incubated for 5 hours at 37°C
with 5% CO2.

RNA Isolation and Quality Assessment
Total RNA was isolated from 1 mL of heparinized whole blood using a QIAamp
RNA Blood Mini Kit (Qiagen, Valencia, CA, USA Cat. No. 52304) according to the
manufacturer’s instructions and then stored at -80°C until use. An on-column DNase
(27.27 Kunitz units) treatment (Qiagen, Valencia, CA, USA Cat. No. 79254) was done
for all samples to remove genomic DNA. RNA was quantified using a Nanodrop ND1000 spectrophotometer using the ND-1000 V3.3.0 software.
RNA quality was assessed using the Agilent RNA 6000 Bioanalyzer. Twelve
samples were analyzed, and an RNA integrity number (RIN) was determined for each.
Cytokine Gene Expression Quantification
Cytokine RT-qPCR results were analyzed by comparing cyclosporine-treated
samples to untreated controls across the various times and temperatures. IL-2 and IFN-γ
genes and reference gene GAPDH expression were quantified via RT-qPCR using a
SuperScript™ III Platinum® SYBR® Green One-Step RT-qPCR kit with Rox used as a
reference dye (Invitrogen, Grand Island, NY, USA Cat no. 11736-059). Primers for IL-2,
IFN-γ, and GAPDH were based on reported GenBank nucleotide sequences as previously
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published by Kobayashi et al, and are shown in Table 2.1.13 All reactions were run on an
Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Life
Technologies Corporation, NY, USA Cat no. 4351106) using 7500 software v2.0.6 for
analysis. The RT-qPCR was performed in a 20µL final volume containing 0.75ng/µL of
template and 200nM of each primer. Thermal cycling parameters were as follows: 50°C
for 3 min, 95°C for 5 min, then 40 cycles of 95°C for 15 sec and 60°C for 30 sec followed
by a melting analysis that comprises 95°C for 15 sec, 60°C for 1 min, after which the
ramp speed decreases from 1.667°C/sec to 0.01667°C/sec and data is collected
continuously until it reaches 95°C, temperature is then held for 30 sec and finally 60°C
for 15 sec. All samples were run in triplicate while non-template controls were run in
duplicate. A no reverse-transcriptase control, using GoTaq® qPCR Master Mix (Promega
Corporation, Madison, WI, USA Cat no. A6001) following the manufacturer’s
instructions, was also included in one run to ensure there was no contaminating genomic
DNA. To calculate the relative change in gene expression for all samples, the 2-∆∆Ct
method was employed using GAPDH as a reference gene where ΔΔCt = (CtGOI –
Ctnorm)treated – (CtGOI – Ctnorm)untreated where GOI is the gene of interest and norm is the
reference gene.14 Cytokine gene expression was presented as a percentage for each time
and temperature combination where the untreated control sample represented 100% gene
expression for IL-2 and IFN-γ.
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Table 2.1

Sequences of primer sets used in the qRT-PCR assay

Primer Set
GAPDH

IL-2

IFN-γ

Primer Sequence (5' - 3')

GenBank Accession Number

Forward

AACTCCCTCAAGATTGTCAGCAA

AB038240

Reverse

CATGGATGACTTTGGCTAGAGGA

Forward

CCTCAACTCCTGCCACAATGT

Reverse

TGCGACAAGTACAAGCGTCAGT

Forward

GCATTCCAGTTGCTGCCTACT

Reverse

ACCAGGCATGAGAAGAAATGCT

U28141

AF126247

Primers used published by Kobayashi et al., 2007

Validation of qRT-PCR Assay
In Vitro Transcription
The PCR products of the three amplified genes were purified using Wizard SV
Gel and PCR Clean-Up System (Promega Corporation, Madison, WI, USA Cat no.
A9281), cloned into pGEM-T Easy Vector (Promega Corporation, Madison, WI, USA)
and propagated into chemically competent DH5premade Z-competent Escherichia coli
cells (Zymo Research, Irvine, CA, USA Cat no. T3007). Purified plasmid DNAs
(PureLink HiPure plasmid miniprep kit, Invitrogen, Grand Island, NY, USA Cat no.
K2100-02) were sent for sequencing (Eurofins MWG Operon, Huntsville, Alabama,
USA). The plasmid quantification was assessed spectrophotometrically and the number
of molecules was determined on the basis of plasmid size and corresponding DNA mass.
One microgram of plasmids previously linearized with restriction enzyme SpeI (New
England BioLabs, Ipswich, MA, USA Cat no. R0133S) were used for the synthesis of the
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recombinant transcripts using MAXIscript T7 in vitro transcription kit (Invitrogen, Grand
Island, NY, USA Cat no. AM1312).
Limit of Detection and qRT-PCR Efficiency
The limit of detection (LOD) of all 3 RT-qPCR assays was determined in
triplicate using 10-fold serial dilutions of recombinant transcripts representing 101 to 106
copies of RNA per reaction.
Assay efficiency was assessed using five 10-fold serial dilutions run in triplicate
of total RNA isolated from one healthy Walker hound. The slope of the resulting curve
was used to calculate assay efficiency using the following equation: Efficiency = -1+10(1/slope)

Inter-assay and Intra-assay Variation
Inter-assay variation was determined by running one sample in triplicate on nine
different days. Intra-assay variation was calculated using the mean and standard
deviation of Ct values for a reaction run in triplicate. This was replicated on nine different
plates, all using the same RNA sample, and the coefficients of variation (CV) calculated
for each run were averaged together. For all measurements, mean value, standard
deviation, and CV were calculated for the threshold cycle (Ct) values.
Statistical Methods
For the storage study, the data were visually assessed for normality using the
UNIVARIATE procedure in SAS for Windows 9.3 (SAS Institute, Inc., Cary, NC) for
both the IL-2 and IFN-γ outcomes. Each outcome was found to be approximately
normally distributed. A mixed model repeated measures analysis was conducted for each
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out-come using the MIXED procedure. Separate models were assessed for each storage
temperature and treatment combination. Time was included in the models as a fixed
effect. The repeated measures of samples taken from the same dog over time were
accounted for in a repeated statement using a first order autoregressive covariance
structure. A random statement with dog as the random effect was used to account for
between-dog variation. Differences in least square means with Dunnett adjustment of pvalues were used for comparisons of the 24 h and 48 h samples to the 0 h cytokine gene
expression levels if time was found to be a significant fixed effect. An alpha level of 0.05
was used to determine significance in all analyses.
Results
RNA Quality
RNA quality was assessed using samples from a variety of storage time and
temperature combinations. RIN values had an average of 8.26 and a range of 7.60-8.60
where a RIN value of 1 represents degraded RNA and a value of 10 represents high
quality intact RNA.
Specificity and Sensitivity
Specificity was assured by melt-curve analysis demonstrating one amplification
peak and sequencing of the amplified products.
Amplified RT-qPCR products that were sent for sequencing were confirmed to be
canine IL-2, IFN-γ and GAPDH sequences using the basic local alignment search tool
(BLAST).
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Regression lines of five 10-fold serial dilutions of total RNA (dilution vs. Ct) had
slopes of -3.51 for GAPDH, -3.58 for IL-2, and -3.58 for IFN- γ (Table 2.2). The
resulting amplification efficiencies were 92.86% for GAPDH, 90.33% for IL-2, and
90.27% for IFN-γ (Table 2.2).
The limit of detection of the assays was determined using 10-fold serial dilutions
of recombinant transcripts and was found to be 1000 copies of a single RNA transcript
for IL-2, IFN- γ, and GAPDH.

Table 2.2

Assay amplification efficiency, slopes of regression lines, and inter-assay
and intra-assay variation for reference gene and cytokine genes

Gene

Efficiency
(%)

Amplification
Factor

Slope

GAPDH

92.86

1.93

IL-2

90.33

IFN-γ

90.27

Inter-assay
Variation

Intra-assay
Variation

CV (%)

SD (Ct)

CV (%)

SD (Ct)

SD Range

-3.51

7.07

1.22

0.24

0.04

0.015 - 0.091

1.90

-3.58

6.97

2.13

0.33

0.098

0.037 - 0.244

1.90

-3.58

4.73

1.49

0.88

0.277

0.039 - 0.382

Assay efficiency for reference gene and cytokine genes determined using five tenfold dilutions (10 1- 106) of
total RNA isolated from a healthy intact female Walker hound. Inter-assay variation determined by running
one sample in triplicate on nine different days. CV was calculated using the mean and standard deviation of
Ct values for one sample run on nine different days. Intra-assay variation was calculated using the mean
and standard deviation of Ct values for a reaction run in triplicate. This was replicated on nine different
plates all using the same RNA sample, and the CVs calculated for each run were averaged together. (CV =
coefficient of variation, SD = standard deviation)

Cytokine Gene Expression
Combined cytokine gene expression data for all 10 dogs in our initial therapeutic
cyclosporine concentration study is shown in Figure 2.1. The data for all 10 animals at
each time and temperature combination were pooled to determine the medians and first
and third quartiles. Only one cyclosporine-treated sample was not suppressed below 50%
of untreated cytokine gene expression. Cytokine gene expression data for all four dogs in
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our subsequent subtherapeutic cyclosporine concentration study is shown in Figure 2.
Adequate RNA was isolated from all samples in our initial 10 dog study after storage for
24 hours, at both 4°C and room temperature, while at 48 hours adequate RNA was
isolated from all 4°C samples, with several room temperature samples having insufficient
RNA extracted for gene analysis. Adequate RNA was isolated from all samples in our
subsequent four dog study at 4°C.
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Figure 2.1

Cytokine gene expression in samples exposed to 500 ng/mL cyclosporine
as a percentage of expression in unexposed samples

Figures presented as median, first and third quartiles (n = 10 dogs except for 48 hour samples at room
temperature, where n = 5 dogs). A IL-2. B IFN-γ.
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Figure 2.2

Cytokine gene expression in samples exposed to 75 ng/mL cyclosporine as
a percentage of expression in unexposed samples

Figures presented as median, first and third quartiles (n = 4 dogs). A IL-2. B IFN-γ.

Inter-assay and Intra-assay Variation
Inter-assay variation for GAPDH, IL-2, and IFN- γ had a CV of 7.07%, 6.97%,
and 4.73%, and a SD of 1.22, 2.13, and 1.49 Ct, and intra-assay variation had a CV of
0.24%, 0.33%, and 0.88%, and a SD of 0.040, 0.098, and 0.277 Ct respectively (Table
2.2).
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Discussion
Optimal cyclosporine treatment protocols have not been established for dogs, in
part due to individual to individual variability in immunosuppressive effects despite
comparable blood concentrations.10 A poor correlation between cyclosporine blood
concentrations and clinical response has been demonstrated with both canine atopy and
inflammatory bowel disease.15,16 Cyclosporine dosing in veterinary cases is therefore
often empirically adjusted based solely on clinical response.
Cyclosporine blood concentrations similarly do not always predict rejection in
human transplant medicine, and this problem has prompted the development of
pharmacodynamic assays of the drug’s biological effects.17-22 While such assays have
proven to be valuable for dosing humans, a practical veterinary counterpart has yet to be
developed.
Previous work in our laboratory evaluated flow cytometry as a method to measure
T-cell cytokine production in dogs in response to oral cyclosporine, and documented
suppressed levels of IL-2 and IFN-γ.10 Flow cytometry requires immediate sample
processing, however, and results can also be influenced by daily variations in machine
setup. Quantitative RT-PCR offers an appealing alternative, as samples are potentially
stable enough to allow standard submission from external sources, and extracted RNA
can also be frozen and saved for batch analysis.13,23,24
In this study, we analytically validated a RT-qPCR panel of NFAT-regulated
cytokine gene expression designed to measure the effect of drugs such as cyclosporine on
T-cell function. Specifically, we evaluated assay repeatability, precision, and accuracy as
well sample stability under different storage conditions. Our results suggest that our assay
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is analytically sensitive and specific, and that blood samples can be kept for up to 48
hours at 4°C, and 24 hours at 4°C or room temperature without loss of interpretable
results. Storage at room temperature for 48 hours was less optimal because of a
diminishment in the amount of RNA that can be extracted.
In the initial storage portion of our study, we demonstrated consistently reduced
cytokine gene expression in response to an in vitro model where whole blood was
incubated with cyclosporine at concentrations comparable to clinically relevant blood
levels (Figure 1). Under a range of storage times and temperatures, gene expression
following incubation with cyclosporine was suppressed below 50% of the degree of
expression in untreated samples in all but one sample. The majority of samples
suppressed to 25% or less, which is a similar degree of cytokine suppression seen in other
studies evaluating cyclosporine at a concentration of 500 ng/mL.25,26 We speculate the
single result which suppressed by less than 50% was a laboratory error, since other
samples collected from the same animal at the same time and run in parallel exhibited
more pronounced suppression of gene expression. Changes in the degree of suppression
of gene expression were not seen over time despite exposure to cyclosporine for up to 48
hours, suggesting that samples from dogs receiving cyclosporine could be mailed by
veterinarians under standard handling conditions without loss of assay validity, despite
the presence of cyclosporine in the submitted sample.
Following our initial storage study, we conducted a smaller study using a lower
concentration of cyclosporine to ensure that prolonged drug exposure over 1-2 days of
storage did not cause a progressive decrease in cytokine gene expression that could be
misinterpreted as evidence of therapeutic efficacy. We conducted this second study at
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4°C only because, based on our initial study, we determined that 4°C was the preferred
temperature for sample submission without excessive loss of extractable RNA.
Compared to exposure to a cyclosporine concentration of 500 ng/mL, exposure of
samples to 75 ng/mL of cyclosporine caused a less consistent reduction in cytokine gene
expression. Importantly, however, sample storage did not increase the degree of
cyclosporine-mediated suppression of gene expression (Figure 2.2).
In order to validate our assays, amplification efficiency, LOD, and inter- and
intra-assay variability were determined. For PCR, amplification efficiency documents
how well the target is amplified by the assay, and amplification efficiencies between 90
and 110% are generally considered acceptable.27 Our assay efficiencies fell with this
range, confirming adequate performance. The LOD assesses the sensitivity of an assay,
and has a minimum theoretical limit of three copies per PCR reaction.28 The LOD for our
assay was determined to be 1000 copies, similar to LODs reported by other groups
developing similar assays.29 Although our LOD is higher than ideal, our target genes are
highly expressed, and typical samples will have sufficient cells with ample gene
expression to ensure a much higher copy number. We therefore expect that the impact of
a higher than optimal LOD on the clinical applicability of our assay will be minimal. In
fact, LOD values lower than those obtained in our study have been shown to be
vulnerable to the Monte-Carlo effect, which can result in inaccurate data.30 The
repeatability and reproducibility of our assay was evaluated by calculating intra-assay
and inter-assay variation. For quantitative assays, a CV value greater than 20% is thought
to result in a significant loss of precision.30 For our assays, CV values for intra- and inter-
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assay variability were less than 10%, suggesting a high level of repeatability and
reproducibility.
In conclusion, our RT-qPCR assays of NFAT-regulated cytokine gene expression
appear to be sensitive, efficient, precise and robust enough to permit evaluation of the
effects of cyclosporine on T-cell function in dogs. Furthermore, samples analyzed using
our assays provide stable results for 24-48 hours under standard handling conditions, and
can therefore be routinely shipped without loss of sample viability.
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ALTERATIONS IN ACTIVATED T-CELL CYTOKINE EXPRESSION IN HEALTHY
DOGS OVER 7 DAYS OF DAILY DOSING WITH ORAL CYCLOSPORINE
Abstract
Cyclosporine is a powerful T-cell inhibitor used in the treatment of immunemediated and inflammatory diseases in the dog. There is limited information on how to
best monitor patients on cyclosporine therapy. Currently, pharmacokinetic assays that
measure the concentration of cyclosporine in the blood are used to assess if the dose is
effective, however target blood drug concentrations have not been shown to reliably
correlate with suppression of T-cell function in the dog. In human transplant recipients,
therapeutic drug monitoring has shifted from a pharmacokinetic to a pharmacodynamic
based approach. Our laboratory has validated a qRT-PCR assay to measure the
pharmacodynamic effects of cyclosporine in the dog. In this study, activated T-cell
expression of IL-2 and IFN-γ was measured using qRT-PCR daily for 7 consecutive days
in 8 healthy Walker hounds receiving cyclosporine at a dosage of 10mg/kg every 12
hours. Cytokine production was found to be markedly decreased within 24 hours after the
initiation of cyclosporine. Based on these results, cyclosporine causes a rapid drop in Tcell cytokine production that is sustained with continued dosing in healthy dogs.
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Introduction
Cyclosporine is a potent immunosuppressive agent used to treat an increasing
number of immune-mediated conditions in the veterinary field. Despite its popularity,
ideal oral cyclosporine dosing protocols for systemic immunosuppression have yet to be
established for the dog. Cyclosporine is a cyclic polypeptide that inhibits T-cell function
by targeting the intracellular phosphatase calcineurin, leading to reduced transcription of
nuclear factor of activated T cells (NFAT) regulated cytokines such as interleukin-2 (IL2) and interferon-gamma (IFN-γ). These cytokines have been shown to be increased in
many immune-mediated and inflammatory conditions, including atopy,1 immunemediated hemolytic anemia (IMHA),2 and anal furunculosis.3-5 Cyclosporine-induced
reduction in the transcription of cytokines under the control of NFAT leads to inhibition
of T-cell function and an overall decrease in humoral and cell-mediated immune
responses.
An ideal oral dosing protocol for the commencement of systemic
immunosuppressive dosages of cyclosporine in the dog has not been established. While
measurement of blood cyclosporine levels was the first established method of estimating
the degree of immunosuppression in canine clinical patients, dogs have been shown to
vary markedly in T-cell response to the same cyclosporine blood concentration.6
Although canine patients may achieve blood drug concentrations within a targeted range,
sufficient immunosuppression may not be achieved in some dogs due to individual
variations in response to cyclosporine. To address this issue, we have developed and
validated a quantitative reverse transcription polymerase chain reaction (qRT-PCR) based
assay that assesses the effects of cyclosporine therapy on T cells in dogs via measurement
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of the Type 1 T helper (Th1) cytokines IL-2 and IFN-γ.7 Utilizing a pharmacodynamic
approach to measure the impact of cyclosporine on T-cell function facilitates a more
targeted assessment of drug effects on the immune status of the patient, and dosage
recommendations and adjustments can be made based on immunosuppressive effects
rather than target drug concentrations. In this current study, we use the qRT-PCR assay to
determine the timing of onset of peak suppression of T-cell function in dogs commencing
oral cyclosporine.
In this investigation, activated T-cell cytokine levels were assessed daily in
healthy Walker hounds treated with immunosuppressive doses of cyclosporine for 7
straight days. The study was designed to facilitate determination of the ideal timing of
sample collection for pharmacodynamic monitoring after the commencement of
cyclosporine therapy in canine patients. We hypothesized that a downward trend of
cytokine production would be observed over the 7 day treatment course, and that
maximal suppression of T-cell function would be attained before the end of the study
period.
Materials and Methods
Experiment and animal care protocols were approved by Mississippi State
University Institutional Animal Care and Use Committee. Mississippi State University is
accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care.
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Blood Sample Collection
Eight Walker hounds, members of a healthy research dog colony, were dosed
every 12 hours with 10 mg/kg of oral modified cyclosporine (Atopica, Greenfield, IN,
USA ) for 7 days. Approximately 3 ml of blood was collected from the jugular vein daily
for 7 days, 2 hours after morning dosing, using a needle and syringe. Samples were
immediately transferred into a heparin tube. Dogs were fed twice daily, and not given
their morning meal until after blood collection. Prior to commencement of drug
administration, a pre-study sample was collected in the same fashion to serve as our
baseline for comparison purposes.
Cyclosporine Blood Concentrations
Whole blood was collected into EDTA anticoagulant tubes 2 hours after oral
dosing on Day 7 of cyclosporine treatment for all 8 dogs, and shipped on ice to the
Auburn University Veterinary Clinical Pharmacology Laboratory for analysis.
Cyclosporine concentrations were measured using a previously described method.8
Briefly, the Siemens (New York, NY, USA) Cyclosporine Immunoassay® (CSA) and the
Siemens Cyclosporine Extended Range Immunoassay® (CSAE) were used to measure
cyclosporine concentrations in canine whole blood samples containing EDTA. All
samples were analyzed with a Siemens (New York, NY, USA) Dimension Xpand Plus®
general chemistry analyzer.
T-Cell Activation
Phorbol myristate acetate (12.5 ng/mL) (Sigma, St.Louis, MO, USA Cat no.
P8139-1MG ) and ionomycin (0.8 µM) (Sigma, St. Louis, MO, USA Cat no. I063473

1MG) were used to activate whole blood samples as previously published by Riggs et al.7
All samples were then incubated for 5 hours at 37°C containing 5% CO2.
RNA Isolation
RNA was isolated using the protocol previously published by Riggs et al.7 Total
RNA was isolated from 1 mL of heparinized whole blood using a QIAamp RNA Blood
Mini Kit (Qiagen, Valencia, CA, USA Cat. No. 52304) following the manufacturer’s
instructions. All samples underwent an on-column DNase (27.27 Kunitz units) treatment
(Qiagen, Valencia, CA, USA Cat. No. 79254). Post collection samples were stored at 80°C until use. A Nanodrop ND-1000 spectrophotometer using ND-1000 V3.3.0 software
(NanoDrop Technologies, Wilmington DE, USA) was used to determine RNA
concentration.
Cytokine Gene Expression Quantification
The results of cytokine qRT-PCR data were evaluated by comparing daily
cyclosporine treatment samples to a pre-treatment baseline sample using protocols
previously published by Riggs et al.7 A SuperScript™ III Platinum® SYBR® Green
One-Step RT-qPCR kit using Rox used as a reference dye (Invitrogen, Grand Island, NY,
USA Cat no. 11736-059) was used to quantify expression of housekeeping gene GAPDH
and genes of interest IL-2 and IFN-γ. Primers used in the reaction were based on
GenBank nucleotide sequences as previously reported by Kobayashi et al.9 All reactions
were run on a Stratagene Mx3500P Multiplex Quantitative PCR system (Agilent
Technologies) using Mx Pro software for analysis. The RT-qPCR reaction was performed
with a final volume of 20µL containing a total of 30ng of template RNA and 200nM of
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each primer. The following thermal cycling parameters were used: 50°C for 3 min, 95°C
for 5 min, then 40 cycles of 95°C for 15 sec and 60°C for 30 sec followed by a melting
analysis that comprises 95°C for 15 sec, 60°C for 1 min, after which the ramp speed
decreases from 1.667°C/sec to 0.01667°C/sec and data is collected continuously until it
reaches 95°C, temperature is then held for 30 sec and finally 60°C for 15 sec. All samples
were run in triplicate, while non-template controls were run in duplicate. ΔCt values of
treatment days were compared to ΔCt value of a pre-treatment sample where ΔCt = CtGOI
– Ctnorm in which GOI is the gene of interest and norm is the reference gene. The 2-∆∆Ct
method was used to determine the relative change in expression using GAPDH as a
reference gene where ΔΔCt = (CtGOI – Ctnorm)treated – (CtGOI – Ctnorm)pre-treatment where GOI
is the gene of interest and norm is the reference gene.10 Cytokine gene expression was
presented as a percentage where the pre-treatment baseline sample represented 100%
gene expression for IL-2 and IFN-γ.
Statistical Analysis
The change in IL-2 ∆Ct and IFN-γ ∆Ct values in response to activation in pretreatment samples was calculated by first subtracting the activated value from the unactivated value for each dog for each cytokine. The distributions of these changes were
then assessed using PROC UNIVARIATE in SAS for Windows 9.4 (SAS Institute, Inc.,
Cary, NC). The change in IL-2 ∆Ct due to activation of pretreatment samples was found
to be normally distributed while the change in IFN-γ ∆Ct was not. A one sample t test
and a Wilcoxon Signed Rank test using PROC UNIVARIATE were conducted to
determine if the changes due to activation were significant for IL-2 ∆Ct and IFN-γ ∆Ct,
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respectively. The effect of day on each of IL-2 ∆Ct and IFN-γ ∆Ct were assessed by
mixed model analysis using PROC MIXED, SAS for Windows 9.4 (SAS Institute, Inc.,
Cary, NC, USA). Separate models were made for each cytokine. For each model, day
was included as the fixed effect and dog identity was included as a random effect. The
effect of repeated measures of each dog over time was accounted for using a repeated
statement with an autoregressive one correlation structure. If the effect of day was found
to be significant, pairwise comparisons were made between the activated pretreatment
value and each of the values for Day 1 to Day 7 using Dunnett’s adjustment for multiple
comparisons of least squares means. The distribution of the conditional residuals was
evaluated for each mixed model to ensure the assumptions of the statistical method had
been met. An alpha level of 0.05 was used to determine statistical significance.
Results
Cyclosporine Blood Concentrations
Day 7 peak (2 hours post-administration) blood cyclosporine concentrations are
presented in Table 3.1. Peak drug concentrations ranged from 1,671 ng/ml to 3,052
ng/ml, with a median of 2,363ng/ml.
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Table 3.1

Cyclosporine Blood Concentrations

1

Cyclosporine blood level
(ng/mL)
2,545*

2

2,678*

3

1,671

4

2,182*

5

1,694

6

3,052*

7

1,949

8

2,983*

Dog

Peak (two hour post-administration) blood concentrations of cyclosporine in 8 dogs after 7 days of oral
modified cyclosporine at 10mg/kg every 12 hours. Results labeled * indicate values were obtained by
dilution.

qRT-PCR
Quantitative RT-PCR results are presented in Figures 3.1 and 3.2 for IL-2 (A) and
IFN-γ (B). In Figure 3.1, ∆Ct values are presented. A statistically significant increase in
∆Ct value, which indicates decreased cytokine expression, was observed for pretreatment un-activated samples and all days of cyclosporine treatment for both IL-2 and
IFN-γ (p-value <0.0001). Cytokine expression is presented as a percentage of an
activated pre-treatment sample taken prior to any drug administration in Figure 3.2. This
shows the significant decrease in IL-2(A) and IFN-γ(B) levels induced by cyclosporine
therapy. Statistical analysis was completed using ∆Ct values. In Figure 3.2 an activated
pre-treatment baseline sample represents 100% cytokine production (not represented in
the figure). An un-activated baseline sample was significantly decreased for both IL-2
and IFN-γ expression compared to the pre-treatment activated baseline sample, indicating
adequate activation of samples (p-value <0.0001). A significant decrease in both IL-2 and
IFN-γ RNA production, compared to pre-treatment, was observed after only 24 hours of
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cyclosporine therapy (P-value <0.0001). All subsequent days of treatment were found to
have a statistically significant decrease in ∆Ct value, compared to pre-treatment, in both
IL-2 and IFN-γ expression (p-value <0.0001). Minimal variation was seen in cytokine
production over the 7 days of cyclosporine administration.

Figure 3.1

∆Ct Values for Interleukin-2 and Interferon-γ

Box plots of whole blood IL-2 (A) and IFN-γ (B) RNA expression for 8 healthy Walker hounds treated for 7 days with
10mg/kg cyclosporine every 12 hours. Expression is presented as ΔCt values where ΔCt = CtGOI – Ctnorm in which GOI is the
gene of interest and norm is the reference gene. The line within each box denotes the median, box edges represent the first
and third quartiles, and whiskers extend to maximum and minimum values. Asterisks represent samples with a
statistically significant change in ∆Ct (p-value < 0.0001) compared to an activated pre-treatment sample. RT-qPCR was
also performed without activation (un-activated) on pre-treatment samples for comparison with activated samples to ensure that
adequate activation was achieved. (IL-2 = interleukin-2, IFN-γ = interferon-gamma, Pre A = pre-treatment activated,
Pre UA = pre-treatment un-activated)
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Figure 3.2

Percent of Pre-Treatment for Interleukin-2 and Interferon-γ

Box plots of whole blood IL-2 (A) and IFN-γ (B) RNA expression presented as a percentage of an
activated pre-treatment baseline sample, in which the pre-treatment sample represents 100% cytokine
production, for 8 healthy Walker hounds treated for 7 days with 10mg/kg cyclosporine every 12 hours. The
line within each box denotes the median, box edges represent the first and third quartiles, and whiskers
extend to maximum and minimum values. All samples were suppressed below 5% for IL-2 (A) and below
3% for IFN-γ (B) compared to an activated pre-treatment sample. Asterisks represent samples with a
statistically significant change in ∆Ct (p-value < 0.0001) compared to an activated pre-treatment sample.
RT-qPCR was also performed without activation (un-activated) on pre-treatment samples for comparison
with activated samples to ensure that adequate activation was achieved. (IL-2 = interleukin-2, IFN-γ =
interferon-gamma, Pre UA = pre-treatment un-activated)
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Discussion
Cyclosporine is used to treat a number of immune-mediated diseases in the dog,
and until recently therapeutic monitoring has standardly consisted of measuring blood
drug concentrations. A qRT-PCR based assay to assess activated T-cell cytokine
production in canine patients undergoing cyclosporine therapy is now available, and has
shown promise for use in clinical cases. However, ideal timing of sample collection for
the qRT-PCR assay after commencement of cyclosporine therapy has not been
established. A previous study demonstrated marked suppression of cytokine production
after 7 days of therapy, but no testing occurred before the Day 7 testing. Thus, no study
has been performed to show the daily effects of cyclosporine on T cells over the initial
dosing period. The goal of this study was to determine ideal timing for sample collection
after the initiation of cyclosporine treatment.
For this study, 8 healthy Walker hounds were given modified cyclosporine orally
at a dose rate of 10mg/kg every 12 hours for 7 days. This dose rate has previously been
established to reliably inhibit T-cell function in dogs.8 Blood was collected 2 hours after
oral dosing each day, and activated T-cell IL-2 and IFN-γ mRNA expression levels were
measured via qRT-PCR. Two hours post-dosing has previously been established to reflect
peak post-administration suppression of cytokine expression.7,11 Cytokine production was
observed to dropped dramatically within the first day of cyclosporine administration. By
Day 1, median IL-2 expression had dropped to 0.53% of pre-treatment values (range
0.30% to 2.26%), and median IFN-γ expression had dropped to 0.40% of pre-treatment
values (range 0.12% to 0.96%). This response is approximately 100 fold greater than the
half maximal inhibitory concentration (IC50) that is standardly used in pharmacodynamic
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assays to measure of the effectiveness of a drug at inhibiting a specific biological
function. A significant decrease in both IL-2 and IFN-γ expression, compared with pretreatment values, was also observed in all subsequent days of therapy. A low degree of
variability, as evidenced by narrow ranges between minimum and maximum values, was
observed throughout the 7 days of the study. The results of this study suggest that
activated T-cell IL-2 and IFN-γ RNA production is markedly decreased within 24 hours
after the initiation of cyclosporine administration in healthy dogs, and that this effect is
sustained throughout one week of drug administration.
Therapeutic drug monitoring (TDM) in dogs on immunosuppressive doses of
cyclosporine is important for a number of reasons. Firstly, there is wide individual-toindividual variability in cyclosporine pharmacokinetics, and the same dose used in two
different patients may not reach the same target blood concentrations. Secondly, a
threshold drug concentration must be achieved to minimize the risk of treatment failure
and, thirdly, toxicity must be avoided by ensuring trough concentrations are within a safe
range.12 Currently, TDM of canine patients on cyclosporine is often accomplished
through measuring peak or trough blood drug concentrations collected 2 hours or 12-24
hours, respectively, after drug administration.11,13 Doses are then adjusted until target
therapeutic blood drug concentrations are achieved. Little research is available in dogs to
support establishment of ideal target peak cyclosporine concentrations, and most
recommendations for systemic immunosuppression are extrapolated from trough
concentrations in renal transplant studies that utilize dogs.3 This pharmacokinetic
approach to TDM, while providing useful information, primarily provides a measurement
of how the body is processing the drug, and does not necessarily reflect cyclosporine’s
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immunosuppressive effects. In fact, previous studies in dogs have established that, at
comparable blood cyclosporine levels, activated T-cell expression of NFAT-regulated
cytokines can be highly variable, thus further emphasizing the need for an individualized
pharmacodynamic approach to clinical patients.14
Peak cyclosporine blood concentrations are presented in Table 3.1 for all 8 dogs
included in the study. The average drug concentration for the group was 2,344ng/mL
which is significantly higher than recommended target concentrations (800-1400ng/mL)
provided by Auburn University Clinical Pharmacology Laboratory, but comparable to
peak cyclosporine concentrations reported in previous studies using the same drug dose
rate.11 Previously, trough cyclosporine concentrations of 500ng/mL have been
recommended in order to achieve adequate immunosuppression.15 The relatively high
peak drug concentrations could account for the significant decrease in cytokine
expression observed in this study. There was significant variation in peak blood
concentrations within the 8 dogs, with a range of 1,671 to 3,052ng/mL, representing a
nearly 90% difference between dogs. This observation demonstrates the importance of
monitoring dogs on cyclosporine therapy, since blood drug concentrations can vary
significantly between dogs receiving similar oral dosages of cyclosporine. This
variability could be the result of a number of factors, including individual variability in
drug absorption and/or excretion mechanisms. This variation in blood drug
concentrations, however, was not reflected in the cytokine assay, as cytokine expression
swiftly decreased in all dogs after only 24 hours of cyclosporine administration and
remained markedly suppressed for the remainder of the study. The consistency of the
cytokine decrease could due to poor assay sensitivity for detecting minor changes in drug
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concentrations at such high blood cyclosporine concentrations, or could indicate that
cytokine expression is maximally suppressed with the given drug concentrations.
Previous research with dogs has shown a marked decrease in activated T cell IL-2
and IFN-γ expression with cyclosporine therapy. For TDM, a practical pharmacodynamic
assay that measures actual T-cell responses to cyclosporine offers an attractive alternative
to measuring blood drug concentrations in canine patients receiving cyclosporine.4,8,9,11,16
A validated assay for dogs on cyclosporine therapy that assesses activated T-cell
expression of NFAT-regulated cytokines has not been available until recently,7 and there
is still limited data on ideal timing for sample collection for monitoring therapy with this
method. In this study, a significant decrease in cytokine production was observed after
only 24 hours of cyclosporine therapy in healthy dogs. This trend was maintained on
subsequent days of treatment over 7 consecutive days. Based on these results, TDM using
the RT-qPCR assay can be commenced as early one day after commencing cyclosporine
therapy.
Additional research is needed to assess the applicability of the qRT-PCR assay for
clinical cases. Firstly, the dose rate used in this current study, 10 mg/kg twice daily, is
relatively high. Based on observational clinical experience with samples submitted
through our laboratory over the past few years, this dose rate markedly suppresses T-cell
function in most (but not all) canine patients, and a lower oral dose rate of between 5 to 8
mg/kg twice daily is sufficient to adequately suppress T-cell function in most patients.
We chose the dosage of 10 mg/kg to ensure reliable suppression of T-cell function for the
purposes of our study, but it is possible that lower dose rates may take longer to effect.
Secondly, anecdotal observations in a limited number of samples obtained over the first
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week of cyclosporine therapy in several canine clinic patients suffering from severe
immune-mediated diseases such as IMHA have suggested that maximal decreases in Tcell function may be delayed for several days compared to healthy dogs. These
preliminary observations suggest that more time may be needed to adequately suppress
cytokine production in clinical canine patients suffering from severe immune-mediated or
inflammatory diseases. Further work is therefore warranted in clinical patients to best
determine ideal timing for sample collection following commencement of cyclosporine
therapy.
In conclusion rapid and sustained suppression of IL-2 and IFN-γ expression is
observed after only 24 hours of cyclosporine administration in healthy dogs. As this assay
is intended for use in clinical cases of immune-mediated and inflammatory-based
diseases in which cyclosporine is used for treatment, the rapid decrease in cytokine
expression may not be reflective of immune system response in these types of patients.
Further research is therefore necessary in clinically affected animals to determine ideal
sample collection timing after starting cyclosporine therapy.
Acknowledgements
This study was funded by the Dr. Hugh G. Ward Endowment. We would like to
thank Dr. Dawn Boothe and the Auburn Clinical Pharmacology Laboratory for assistance
with blood cyclosporine concentrations.

84

Conflict of Interest
The authors are affiliated with the Mississippi State University Pharmacodynamic
Laboratory, which provides the assay evaluated in this study as a commercial service to
veterinarians.

85

References
1. Nuttall TJ, Knight PA, McAleese SM, Lamb JR, Hill PB. Expression of Th1, Th2 and
immunosuppressive cytokine gene transcripts in canine atopic dermatitis. Clinical
and Experimental Allergy 2002;32:789-795.
2. Kjelgaard-Hansen M, Goggs, R., Wiinberg, B., Chan, D.L. Use of serum
concentrations of interleukin-18 and monocyte chemoattractant protein-1 as
prognostic indicators in primary immune-mediated hemolytic anemia in dogs.
Journal of Veterinary Internal Medicine 2011;25:76-82.
3. Archer TM, Boothe DM, Langston VC, Fellman CL, Lunsford KV, Mackin AJ. Oral
cyclosporine treatment in dogs: A review of the literature. Journal of Veterinary
Internal Medicine 2014;28:1-20.
4. Tivers MS, Catchpole B, Gregory SP, House AK. Interleukin-2 and interferon-gamma
mRNA expression in canine anal furunculosis lesions and the effect of ciclosporin
therapy. Veterinary Immunology and Immunopathology 2008;125:31-36.
5. House A, Gregory SP, Catchpole B. Expression of cytokine mRNA in canine anal
furunculosis lesions. Veterinary Record 2003;153:354-358.
6. Archer TM, Fellman CL, Stokes JV, Pinchuk LM, Lunsford KV, Pruett SB, Langston
VC, Mackin AJ. Pharmacodynamic monitoring of canine T-cell cytokine
responses to oral cyclosporine. Journal of Veterinary Internal Medicine
2011;25:1391-1397.
7. Riggs C, Archer T, Fellman C, Figueiredo AS, Follows J, Stokes J, Wills R, Mackin
A, Bulla C. Analytical validation of a quantitative reverse transcriptase
polymerase chain reaction assay for evaluation of T-cell targeted
immunosuppressive therapy in the dog. Veterinary Immunology and
Immunopathology 2013;156:229-234.
8. Fellman C, Archer TM, Stokes JV, Wills RW, Lunsford KV, Mackin AJ. Effects of
oral cyclosporine on canine T-cell expression of IL-2 andIFN-gamma across a 12h dosing interval. Journal of Veterinary Pharmacology and Therapeutics
2016;39:237-244.
9. Kobayashi T, Momoi Y, Iwasaki T. Cyclosporine A inhibits the mRNA expressions of
IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells.
Journal of Veterinary Medical Science 2007;69:887-892.
10. Livak KJ, Schmittgen, T.D. Analysis of relative gene expression data using real time
quantitative PCR and the 2∆∆CT method. Methods 2001;25:402-408.

86

11. Fellman CL, Archer TM, Stokes JV, Wills RW, Lunsford KV, Mackin AJ. Effects
of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a
12-h dosing interval. Journal of Veterinary Pharmacology and Therapeutics
2016;39:237-244.
12. Ptachcinski RJ, Venkataramanan, R., Burckart, G.J. Clinical pharmacokinetics of
cyclosporin. Clinical Pharmacokinetics 1986;11:107-132.
13. Guaguere E, Steffan J, Olivry T. Cyclosporin A: a new drug in the field of canine
dermatology. Veterinary Dermatology 2004;15:61-74.
14. Archer TM, Fellman CL, Stokes JV, Pinchuk LM, Lunsford KV, Pruett
SB, Langston VC, Mackin AJ. Pharmacodynamic monitoring of canine T-cell
cytokine responses to oral cyclosporine. Journal of Veterinary Internal Medicine
2011;25:1391-1397.
15. Daigle JC. More economical use of cyclosporine through combination drug therapy.
Journal of the American Animal Hospital Association 2002;38:205-208.
16. Fellman CL, Stokes JV, Archer TM, Pinchuk LM, Lunsford KV, Mackin AJ.
Cyclosporine A affects the in vitro expression of T cell activation-related
molecules and cytokines in dogs. Veterinary Immunology and Immunopathology
2011 140:175-180.

87

ACTIVATED WHOLE BLOOD CYTOKINE EXPRESSION IN HEALTHY DOGS
COMPARED TO DOGS DIAGNOSED WITH INFLAMMATORY BOWEL
DISEASE OR IMMUNE-MEDIATED HEMOLYTIC ANEMIA
Abstract
Immune-mediated diseases in dogs can be difficult to manage. Cyclosporine is an
immunosuppressive agent being used with an increased frequency for treatment of a
growing number of inflammatory and immune-based diseases in veterinary medicine.
Cyclosporine is a potent T-cell inhibitor and, until recently, an objective assessment of its
effects on target cells was not available. A PCR-based pharmacodynamic assay which
measures cytokine production is now available to assist with determining ideal dosing
protocols for canine patients with diseases such as immune-mediated hemolytic anemia
(IMHA) and inflammatory bowel disease (IBD). In this study, expression of the T-cell
cytokines interleukin-2 (IL-2) and interferon-γ (IFN-γ) cytokine were determined via
qRT-PCR, after an activation step, in canine patients diagnosed with either IMHA or IBD
before receiving cyclosporine therapy, and compared to cytokine expression in healthy
dogs. Both IL-2 and IFN-γ expression were found to be significantly decreased in IMHA
patients compared to the other two groups. A significant difference was not observed
between healthy dogs and those diagnosed with IBD. This finding did not support our
original hypothesis that cytokine production would be increased in dogs with immune88

mediated diseases due to the pro-inflammatory nature of the disease pathogenesis. We
suspect our finding may have been due to the effects of other immunosuppressant agents,
since the only criteria for inclusion in the study population was that cyclosporine could
not have been used for treatment.
Introduction
The immune system includes a complex organization of cells, antibodies and proinflammatory molecules with specific functions which are in place to protect the body
from disease. Occasionally, however, these complex protective mechanisms can lead to
the immune-mediated destruction of host tissues after a breakdown in self-tolerance. The
cytokines interleukin-2 (IL-2) and interferon-γ (IFN-γ) are pro-inflammatory molecules
produced by lymphocytes within the immune system, primarily T cells, with IL-2 serving
to promote B and T cell proliferation,1 and IFN-γ serving to activate macrophages.2 In the
human literature, IL-2 and/or IFN-γ levels are increased in many immune-mediated
conditions, including inflammatory bowel disease (IBD),3,4 atopic dermatitis,5,6
autoimmune hemolytic anemia (AIHA),7,8 and immune-mediated thrombocytopenia
(IMT).9 This trend is paralleled in dogs, with IL-2 and/or IFN-γ levels increased in
atopy,10 immune-mediated hemolytic anemia (IMHA),11,12 and anal furunculosis.13,14 In
contrast, IL-2 levels in cases of canine IBD are reported to vary, with some studies
demonstrating increased levels,15 some studies revealing decreased levels,16 and other
studies showing no significant change at all.17
Cyclosporine is a powerful immunosuppressive agent used in the field of
veterinary medicine to treat an increasing number of inflammatory and immune-mediated
diseases. Over the past few years, the Pharmacodynamic Laboratory at the Mississippi
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State University College of Veterinary Medicine (MSU-CVM) has been developing
useful biomarkers for monitoring cyclosporine therapy in canine clinical patients.
Cyclosporine is a calcineurin inhibitor that serves to reduce T-cell production of nuclear
factor of activated T cell (NFAT) related cytokines such as IL-2 and IFN-γ. Recently, we
validated an assay that measures activated whole blood expression of the RNA coding for
the cytokines IL-2 and IFN-γ via quantitative reverse transcription polymerase chain
reaction (qRT-PCR) in healthy dogs,18 and are now using this assay in clinical patients to
assess the effectiveness of cyclosporine therapy, and to adjust doses accordingly.
This current study was undertaken in order to determine NFAT-related cytokine
levels in canine patients with either IMHA or IBD before commencing cyclosporine
therapy, and compare these to cytokine levels found in normal healthy dogs. The
inflammatory bowel diseases are a group of gastrointestinal disorders characterized by
inflammatory cell infiltrate of the gastrointestinal tract.19 While the exact causes of IBD
are not precisely determined, there is strong suspicion of underlying immune-mediated
pathology.20 IMHA is a type II hypersensitivity reaction in which antibodies target red
blood cells for destruction. Compared to IBD, which is primarily localized to the
gastrointestinal tract, IMHA is considered more of a systemic disease, since red blood
cells distributed throughout the body are vulnerable to destruction. Given the
inflammatory nature of both IBD and IMHA, we hypothesized that unactivated and
activated T-cell production of IL-2 and IFN-γ would be higher in dogs with these
diseases compared to normal dogs. Given the more systemic nature of IMHA, we also
suspected that NFAT-regulated cytokine expression would be higher in dogs with IMHA
compared to those suffering from IBD. Both IBD and IMHA in dogs are commonly
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treated with cyclosporine. Since baseline (pre-treatment levels) of cytokine expression
have the potential to have an impact on levels following treatment with cyclosporine, our
study was designed to determine if baseline NFAT-regulated cytokine expression was
different in dogs with IMHA or IBD compared to normal dogs.
Materials and Methods
Patient Selection
Nine adult female Walker hounds, part of a research dog colony, were used for
the healthy control treatment group. Clinical patients with either IBD or IMHA were
recruited for this study over a period of 3 years. Dogs diagnosed with IBD or IMHA were
either recruited from MSU-CVM Small Animal Internal Medicine service, or from other
boarded veterinary internal medicine specialists throughout North America. Samples
received from specialists outside of MSU-CVM were shipped to the Pharmacodynamic
Laboratory overnight on ice. The effect of shipping and handling on sample analysis was
addressed in a previous study, and provided samples were processed within 2 days of
collection and stored and transported on ice, shipping and handling was found to have no
significant impact on results.18 All subjects included in the study had yet to receive a dose
of cyclosporine. Informed owner consent was obtained for all patients before inclusion in
the study. IBD cases were confirmed via endoscopic biopsy of the gastrointestinal tract
with histopathology evaluated by a board certified pathologist. IMHA cases were
diagnosed based on standard clinical criteria with no evidence of secondary causes of
anemia identified.
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Blood Sample Collection
Approximately 3mL of whole blood was collected from each dog from the jugular
vein with a needle and syringe and immediately inserted into a heparin tube to prevent
coagulation. Samples were stored at 4ᴼC or shipped on ice before cell activation.
T-Cell Activation
Whole blood samples were activated using the protocol previously described by
Riggs et al., with the reagents phorbol myristate acetate (PMA; 12.5 ng/mL) (Sigma,
St.Louis, MO, USA Cat no. P8139-1MG ) and ionomycin (0.8 µM) (Sigma, St. Louis,
MO, USA Cat no. I0634-1MG).18 Samples were then incubated for 5 hours at 37°C with
5% CO2.
RNA Isolation
Isolation of total RNA from samples (both activated and unactivated) was
completed using the protocol previously described by Riggs et al.18 A QIAamp RNA
Blood Mini Kit (Qiagen, Valencia, CA, USA Cat. No. 52304) was used per
manufacturer’s instructions. An on-column DNase (27.27 Kunitz units) treatment
(Qiagen, Valencia, CA, USA Cat. No. 79254) removed potential contaminating DNA. To
measure RNA concentration, a Nanodrop ND-1000 spectrophotometer using the ND1000 V3.3.0 software (NanoDrop Technologies, Wilmington DE, USA) was used.
Samples were stored at -80°C until PCR analysis.
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Cytokine Gene Expression Quantification
Expression of cytokines of interest was assessed in healthy dogs, and in those
diagnosed with either IBD or IMHA. IL-2 and IFN-γ levels were measured with qRTPCR. GAPDH was included in the study as the reference gene. Primers used for the
genes included in the study were based on previously reported nucleotide sequences by
Kobayashi et al.21 A SuperScript™ III Platinum® SYBR® Green One-Step RT-qPCR kit
containing the reference dye ROX (Invitrogen, Grand Island, NY, USA Cat no. 11736059) was used to quantify GAPDH, IL-2, and IFN-γ expression. The reactions were
analyzed with a Stratagene Mx3500P Multiplex Quantitative PCR system (Agilent
Technologies) using Mx Pro software for analysis. All reactions had a final volume of
20µL containing a total of 15ng of template RNA and 200nM of each primer. Thermal
cycling parameters were followed as previously published by Riggs et al.18 All samples
were run in triplicate while non-template controls were run in duplicate. To compare gene
expression, ΔCt values were determined for each individual dog using GAPDH as a
reference gene where ΔCt = CtGOI – Ctnorm. GOI is the gene of interest and norm is the
reference gene. The difference between gene expression in activated and unactivated
samples for each group was also calculated as the ∆∆Ct, where ∆∆Ct = ∆Ct Unactivated ∆Ct Activated. The Ct value represents the cycle number at which sample fluorescence
reaches a threshold level, therefore samples with a lower Ct value require fewer cycles to
for the target nucleotides to be detected, and consequently have higher gene expression
compared to a sample with a higher Ct value.

93

Statistical Analysis
The effects of activation, group (normal, IBD, IMHA), and their interaction on
IL-2 ΔCt and IFN-γ ΔCt were tested in separate linear mixed models using PROC
MIXED in SAS for Windows 9.4 (SAS Institute, Inc., Cary, NC). Dog identity was
included in the models as a random effect. Separate linear models were also fit to
determine if there were differences among the three treatment groups for IL-2 ΔΔCt and
IFN-γ ΔΔCt using PROC MIXED. Differences in least squares means with the simulate
adjustment for multiple comparisons were determined for significant main effects or
interaction terms. Diagnostic plots of residuals for each outcome were assessed to ensure
the assumptions of the statistical method had been met. An alpha level of 0.05 was used
in determining the significance of results.
Results
Patient Profiles
Age, sex, and breed of dogs included in the study are presented in Table 4.1.
Nine healthy female Walker hounds from a research colony were used for the
control group. The group had a median age of 4 years with a range of 2-9 years. All were
intact females (n=9).
Nine patients were recruited into the IBD group, with a median age of 6 years,
ranging from 21 months to 13 years. Within this group, 4 dogs were neutered males, 1
was an intact male, and 4 were spayed females. Breeds represented included Yorkshire
terrier (n=2), dachshund (n=1), Shih Tzu (n=1), rat terrier (n=1), beagle (n=1), pit bull
terrier (n=1), goldendoodle (n=1), and boxer (n=1). Cases were confirmed via
endoscopic biopsy of the gastrointestinal tract with histopathology evaluated by a board
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certified pathologist. As per study requirements, none of these patients had received any
cyclosporine, however some had received other immunosuppressive agents, including
prednisone (n=2), azathioprine (n=1), or zonisamide (n=1).
Nine patients were recruited into the IMHA group, with a median age of 7 years,
ranging from 3 to 8 years. Within this group, there were 3 neutered males, 1 intact male,
and 5 spayed females. Breeds represented included dachshund (n=2), Newfoundland
(n=1), Maltese (n=1), pit bull terrier (n=1), cattle dog cross (n=1), beagle (n=1),
Doberman pinscher (n=1), and miniature schnauzer (n=1). Diagnosis was made by the
presence of evidence of an immune-mediated process against red blood cells (either
spherocytosis, slide agglutination positive, or Coomb’s test positive) as well as no other
evidence of a disease process causing the anemia. As per study requirements, no patients
in this group had received any cyclosporine, however some were already receiving other
immunosuppressive agents, including prednisolone (n=1), dexamethasone (n=1), and/or
azathioprine (n=1).
Table 4.1

Case Profiles

Age (years)
Sex
Number of Breeds
Represented
Median
Range
MN MI FS
FI
IBD
6
1-13
4
1
4
0
8
IMHA
7
3-8
3
1
0
5
8
Healthy
4
2-9
0
0
0
9
1
Profiles of cases (n = 9 per treatment group) selected for study denoting age, sex, and breeds included.
(IBD = inflammatory bowel disease, IMHA = immune-mediated hemolytic anemia, MN = male neutered,
MI = male intact, FS = female spayed, FI = female intact).
Diagnosis

Interleukin-2
Interleukin-2 RNA expression quantified via qRT-PCR for all three groups is
presented in Figure 4.1 (A). P-values for comparison between group ∆Ct values are
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presented in Table 4.2. A statistically significant difference was found between activated
and unactivated samples for all groups (p-value < 0.0001), indicating adequate activation
of all samples. Activated samples had a significantly higher expression level of IL-2,
denoted by a lower ∆Ct value. Patients diagnosed with IMHA were found to have a
significantly lower IL-2 production (higher ∆Ct value) in activated samples compared to
healthy dogs (p-value 0.046) and those with IBD (p-value < 0.0005). This same
difference was observed for unactivated samples as well for both healthy (p-value
0.0006) and IBD (p-value 0.0029) group comparisons. No significant difference was
found between healthy dogs and those with IBD for activated samples (p-value = 1) nor
for unactivated samples (p-value < 0.0789).
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Figure 4.1

Interleukin-2 and Interferon-γ ∆CT

Box and whisker plots of IL-2 (A) and IFN-γ (B) RNA expression from canine whole blood presented as
∆Ct value where ∆Ct = Ct IL2- Ct GAPDH in 9 dogs grouped as either healthy or diagnosed with IBD or
IMHA. A lower ∆Ct represents a higher level of gene expression. Lines within each box represent the
median, box bottom and top represent the first and third quartiles respectively, and whiskers range to
maximum and minimum values obtained. In groups labeled with the same letter, a statistically significant
difference was not found (p-value >0.05). (UA = unactivated, A = activated, IBD = inflammatory bowel
disease, IMHA = immune-mediated hemolytic anemia, IL-2 = interleukin-2).
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Interferon-γ
Interferon-γ RNA expression measured by qRT-PCR for all three groups is
presented in Figure 4.1 (B). P-values for comparison between group ∆Ct values are
presented in Table 4.2. A statistically significant difference was found between activated
and unactivated samples for all groups (p-value <0.0001), indicating adequate activation
of all samples. All activated samples had a lower ∆Ct value, indicating increased level of
expression of IFN-γ in relation to unactivated samples. Dogs in the IMHA group had the
lowest IFN-γ production (highest ∆Ct value) compared to the IBD group (p-value
0.0010) and healthy dogs (p-value 0.0406). No difference was seen between healthy dogs
and those with IBD (p-value = 0.9965).
Table 4.2

∆CT P-values
P-value

Comparison of ∆CT
Healthy v IBD
Healthy V IMHA
IBD v IMHA

IL-2
Act
Un-Act
1
0.0789
0.0456 0.0006
0.0005 0.0029

IFN-γ
Act
Un-Act
0.9965 0.9965
0.0406 0.0406
0.0010 0.0010

P-values for ∆CT comparison between treatment groups. An alpha level of 0.05 was used in determining
the significance of results. (UA = unactivated, A = activated, IBD = inflammatory bowel disease, IMHA =
immune-mediated hemolytic anemia, IL-2 = interleukin-2, IFN-γ = interferon-γ)

Differences Between Activated and Unactivated Samples
Figure 4.2 depicts the difference between activated and unactivated samples for
each group, measured as ∆∆Ct. A higher ∆∆Ct value indicates a larger difference
between activated and unactivated samples. Dogs with IBD were found to have a higher
difference between activated and unactivated samples compared to the healthy control
group for IL-2 (p-value = 0.0279). No difference was found when comparing healthy
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dogs to those with IMHA (p-value = 0.0875) or when comparing dogs with IBD to those
with IMHA (p-value 0.8521). A significant difference was not found for IFN-γ across the
three groups (Figure 4.2) (p-value = 0.4218).

Figure 4.2

Interleukin-2 and Interferon-γ ∆∆CT

Box and whisker plots of difference between activated and unactivated IL-2 (A) and IFN-γ (B) expression from
canine whole blood presented as ∆∆Ct value where ∆∆Ct = ∆Ct UA - ∆Ct A in 9 dogs grouped as either healthy
or diagnosed with IBD or IMHA. A higher ∆∆Ct value indicates a larger difference between activated and
unactivated samples. Lines within each box represent the median, box bottom and top represent the first and third
quartiles respectively, and whiskers range to maximum and minimum values obtained. Treatments that share the
same letter are not significantly different. No difference was found between treatment groups for IFN-γ (p-value
= 0.42). (UA = unactivated, A = activated, IBD = inflammatory bowel disease, IMHA = immune-mediated
hemolytic anemia, IL-2 = interleukin-2, IFN-γ = interferon-γ)
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Discussion
In this study, unactivated and activated whole blood expression of the RNA
coding for the NFAT regulated cytokines IL-2 and IFN-γ was compared between healthy
dogs and dogs diagnosed with either IMHA or IBD prior to the onset of cyclosporine
therapy. IBD and IMHA were selected so that cytokine expression could be compared
between a relatively localized immune-mediated disease process (IBD) and a process that
would be expected to affect the patient on a more systemic level (IMHA).
IBD is characterized by chronic inflammation of the gastrointestinal tract. While
it is a relatively localized disease compared to IMHA, systemic biomarkers of
inflammation, such as C-reactive protein (CRP), are known to be increased in canine IBD
patients. C-reactive protein is a positive acute phase protein produced by the liver in
response to inflammation. Assays that measure CRP concentration are already in use for
monitoring canine IBD progression and response to treatment. It is therefore reasonable
to assume that T cells in the systemic circulation in dogs with IBD would be more
reactive, and thus have higher cytokine production, compared to clinically normal dogs.
Previous research on NFAT-regulated cytokine production in canine patients with IBD
has yielded mixed results. The majority of experiments quantified cytokines from
intestinal biopsy samples and thus reflect cytokine expression at a local level. No study
has focused on activated whole blood samples, which are more reflective of systemic Tcell function. Some studies of local gastrointestinal cytokines have found increased
cytokine production,15 some studies have found decreased production,16 and other studies
have found minimal change17 when compared to a healthy control population. Peters et
al. found no difference in local IL-2 or IFN- γ expression when compared to a control
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population. However, the study population included both patients with IBD and patients
with antibiotic-responsive diarrhea, and the control group used included dogs undergoing
endoscopy for gastroesophageal disease or euthanized for other clinical reasons, and
therefore could potentially have had high cytokine levels compared to normal healthy
animals. In a more recent study by Jergens et al., decreased local IL-2 and IFN- γ levels
were found in dogs with small intestinal IBD when compared to control dogs. This study
had a relatively large sample population (n=48) compared to previous reports, and
evaluated both small intestinal and colonic biopsy samples. However one limitation to the
study was the use of semi-quantitative RT-PCR, which is known to be less sensitive and
not as accurate as real-time RT-PCR.22 None of the previously described studies
measured cytokine expression of activated T cells in dogs with IBD. T-cell activation can
help to unmask cytokine expression differences that may not be as apparent in
unactivated samples, since activation causes maximal cytokine expression. In our study,
utilizing activation with PMA and ionomycin in order to maximize T-cell cytokine
production, a significant difference in ∆CT value was not found between patients
diagnosed with IBD and healthy control dogs for either IL-2 or IFN-γ expression. IBD is
a relatively localized disease, therefore systemic cytokine levels may not be affected
since our assay measures whole blood cytokine expression levels, and may be more
reflective of systemic inflammatory responses. Although none of the tested patients had
received cyclosporine, other immunosuppressive agents the patients received included
prednisone (n=2), azathioprine (n=1), or zonisamide (n=1), and this may also have had an
effect on cytokine production. Another explanation for the observed lack of difference
between normal dogs and dogs with IBD may be related to disease duration in patients
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included in the study. Cytokine patterns are known to change with time in human
Crohn’s disease23 therefore it is possible that the IBD patients included in this study were
in the early phase of disease, and would have cytokine levels more comparable to a
healthy animal.
IMHA is a type II hypersensitivity reaction in which the immune system targets
red blood cells for destruction. Previous studies measuring IL-2 production in IMHA
patients have found increased levels of NFAT-regulated cytokines such as IL-2.7,8,11,12
Abnormal cytokine levels in cases of IMHA have been reported in both human and
veterinary literature. A report by Fagiolo and Toerenzi found increased IL-2 in both
activated and unactivated supernatant samples from humans with autoimmune hemolytic
anemia (AIHA) prior to any pharmacological therapy.8 Comparatively, IFN-γ levels were
not statistically different when compared to a healthy control group. Studies in canine
patients have yielded similar results,12,24 although none have analyzed activated whole
blood samples, which as previously mentioned maximizes T cell cytokine production.
One study by Johnson et al. analyzed serum cytokine levels via Luminex multiplex bead
assay, and found elevated expression levels of T cell cytokines in both IMHA and sepsis
patients. IFN-γ levels were not evaluated in this study. Due to the limited power of the
study, however, individual cytokine levels could not be compared between study groups.
A more recent report by Swann et al. used qRT-PCR to measure IFN-γ and
chemiluminescent assays to measure serum IL-2 in dogs with IMHA. Dogs with IMHA
had not received any immunosuppressive therapy, and were found to have significantly
higher IL-2, but no difference in IFN-γ production, compared to healthy control animals.
In our study, in contrast, cytokine production was found to be significantly reduced
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within activated samples from dogs with IMHA compared to the healthy dog population
or the IBD group. This finding is unexpected, since our original hypothesis was that
baseline cytokine production would be increased in patients with a systemic disease as
IMHA when compared to a healthy control group. We theorize that the observed trend
was in part due to the criteria for case selection. For inclusion in this study, cases were
only excluded if cyclosporine had been started, however use of other immunosuppressive
agents was allowed. The assay used in this study has been shown to primarily reflect the
pharmacodynamic effects of cyclosporine since it measures the drug’s primary molecular
targets and, in human medicine, this assay is typically considered to be unaffected by the
presence of other immunosuppressive drugs. The effects of steroids and other
immunosuppressive agents such as azathioprine on this specific assay, however, have yet
to be fully explored in dogs. It is possible that the other immunosuppressive medications
administered to some of the IMHA patients prior to cyclosporine had an effect on
cytokine production, leading to the observed decrease seen in this group as compared to
the normal dog population. Further research in this area is therefore warranted to explore
the potential effects of drugs other than cyclosporine on our activated whole blood
cytokine expression assay. Another possible explanation for the observed trend could be
due to difference in circulating T-cell number between healthy dogs and those with
IMHA. IMHA patients typically present with lymphopenia and patients included in the
study had a lymphocyte count ranging from 226-535/µL (n=5) which was below the
reference range of 1000-1400/ul. It is possible that the low lymphocyte count contributed
to the reduced IL-2 and IFN-γ expression observed in this study as higher cytokine
expression levels would be expected with an increasing lymphocyte count.
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When differences between activated and unactivated samples were compared
between the study groups, for IL-2 expression healthy dogs were found to have a smaller
change following activation compared to dogs with IBD. No difference was found
between IBD and IMHA study populations or between healthy dogs and IMHA groups.
Our results suggest that T cells in dogs with IBD have a higher potential for activation
compared to normal dogs. We suspect that the lack of the same detectable effect in dogs
with IMHA may be due to the effects of other immunosuppressive drugs already being
used for treatment, leading to reduced T cell susceptibility to activation or is the result of
lymphopenia since a low circulating T-cell number would not be able to produce as many
pro-inflammatory cytokines. Preliminary observations in our laboratory in clinical
samples from dogs that have already started cyclosporine tends to mirror this trend, as
dogs on lower cyclosporine doses have a tendency to have a greater difference between
activated and unactivated samples compared to dogs on high cyclosporine doses, in
which there is maximal suppression of T cells and thus minimal difference between
activated and unactivated IL-2 expression. While this effect is expected in dogs receiving
cyclosporine, it was unexpected in dogs receiving glucocorticoids and other
immunosuppressive agents, and warrants further exploration. This same trend was not
observed with IFN-γ, since no difference was detected between study group ∆∆Ct values.
The assay used in this study is currently being used in clinical patients to monitor
immunosuppression in patients on cyclosporine. Whole blood sample IL-2 expression
collected after starting cyclosporine treatment is compared to a baseline or pre-treatment
sample when such a sample is available. The decrease in IL-2 reflected in ∆∆Ct values is
used as a marker of immune system suppression in the patient, to determine if
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cyclosporine is exhibiting its maximal effect. Recommendations on adjusting
cyclosporine dosage are then made based on assay interpretation. The pathogenesis of
disease and pharmacokinetics of cyclosporine are both considered with assay
interpretation. For example, many cases of canine atopy receiving cyclosporine display
relatively low levels of cytokine suppression using the assay, even though clinically
patients are responding well to therapy. This is most likely due to concentration of
cyclosporine in the skin, with locally high levels of the drug suppressing cytokine
production, a phenomenon which would not be adequately reflected in a more systemic
assay. A similar pattern is seen with cases of IBD, and we suspect this is also due to a
local effect of cyclosporine at the level of the gastrointestinal tract, an effect that is not
reflected in our assay.
Since obtaining a pre-treatment sample can be difficult, our assay can also use
unactivated samples from the same patient during treatment for comparison. Activating T
cells as part of our assay allows for maximum cytokine production and, since effective
cyclosporine treatment markedly suppresses cytokine production, even in activated cells,
activation serves to highlight the effects of the drug. Comparing unactivated and
activated samples post-treatment, rather than pre- and post-treatment samples from the
same patient, eliminates the need for pre-treatment samples. Elimination of the need for
a pre-treatment sample is more convenient for veterinarians, who often don’t have the
opportunity to collect samples prior to therapy. Additionally, variations in baseline assay
results seen with some diseases prior therapy, as was seen with the IMHA patients in this
study, has the potential to have less impact on final result if pre-treatment samples are not
used to calculate post-treatment T-cell responses.
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Our study was the first study to use a PCR-based technique on activated samples
to assess the effect of diseases such as IMHA or IBD on T-cell cytokine production.
Although our assay measured the RNA coding for NFAT-regulated cytokines, and not
actual protein levels, results from previous research comparing this technique to those
that measure cytokine amounts have comparable results.25 The use of qRT-PCR
eliminates the challenge of finding canine antibodies which are not as widely available,
compared to primers, which can be designed for potentially any gene of interest. This
technique also does not require immediate analysis, as RNA can be stored for batch
analysis.
In conclusion, our study found decreased expression of the NFAT-regulated
cytokines IL-2 and IFN-γ in canine patients with IMHA compared to a healthy control
group. These results are in contrast to previous studies which observed increased IL-2
expression in IMHA study populations although, since our study is the first to add an
activation step, results may not be directly comparable. Dogs diagnosed with IBD were
found to have cytokine levels similar to the healthy control population. Our results are
complicated by the fact that some patients with IBD or IMHA received
immunosuppressive agents other than cyclosporine. More research is needed to determine
the effects of immunosuppressive agents other than cyclosporine on activated T-cell
cytokine production in normal dogs, and in dogs with immune-mediated diseases. This
study addressed two immune-mediated diseases, but there are a number of other immunemediated conditions in veterinary medicine in which cyclosporine is prescribed,
including atopy, immune-mediated thrombocytopenia, and anal furunculosis. Further
research into cytokine profiles of patients with these other conditions is also warranted.
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CONCLUSIONS AND FUTURE DIRECTIONS
Inflammatory or immune-mediated diseases in dogs often require chronic or
lifelong treatment with immunosuppressive agents. Such conditions can also be
headaches to manage for both owner and veterinarian, since it can be challenging to
determine the perfect combination of drugs needed to quell the immune system.
Cyclosporine has been used to treat a number of immune-mediated diseases in veterinary
medicine; however it is difficult to predict patient responses to the drug since not all
animals are adequately suppressed with the same oral dose rate. In this dissertation, a
pharmacodynamic assay was developed that allows clinicians to determine if the given
dose of cyclosporine is appropriate for the individual canine patient. The assay utilizes
qRT-PCR to quantify activated T-cell production of interleukin-2 (IL-2) and interferon-γ
(IFN-γ), and the suppression of these cytokines is used to assess patient responses to
cyclosporine. The assay was validated for use in clinical patients by first analyzing the
effect of shipping and handling on samples. A seven day study in healthy dogs was then
used to determine ideal timing of sample collection for pharmacodynamic monitoring
after commencement of therapy. Finally, pre-treatment levels of cytokine expression in
dogs with several common immune-mediated diseases were evaluated, in order to
determine whether pre-existing disease affected cytokine levels.
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As our laboratory has gathered more samples and data associated with using our
assay, our group realized the need to modify the way we approached data analysis. The
assay was originally developed and validated to measure two cytokines, IL-2 and IFN-γ,
both of which are known to be suppressed by cyclosporine. We found that, when
quantifying these in clinical cases, IFN-γ tended to be quite variable and did not correlate
well clinically with the case outcome and reported response to therapy, while IL-2 tended
to provide more predictable results. This led to the laboratory moving to using only IL-2
for analysis. We also initially hypothesized that a pre-treatment sample would be required
to adequately determine the level of suppression for a given patient, and would need to be
available for comparison with a post-treatment sample collected after the start of
cyclosporine therapy. However, we found that we could get consistently similar
interpretation of final results by comparing patient post-treatment results to a healthy dog
control sample. This made coordination of sample collection much easier for practicing
clinicians, who tended to forget to take a blood sample before starting therapy. Our
initial data interpretation involved assessing ∆∆CT, which takes into account either results
from a pre-treatment sample or a healthy control dog in order to compare cytokine
production with and without exposure to cyclosporine. However, we found that this did
not correlate well with the reported clinical case outcome, and thus shifted our focus to
∆CT, which does not require a pre-treatment sample. Samples are instead compared to a
healthy control dog run on the same plate. We also now compare the change in ∆CT value
between an activated and unactivated sample and analyze the change in activation in the
clinical patient receiving cyclosporine compared to a dog with a normal functioning
immune system. Based on the change in activation, patients are categorized into a certain
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subcategory which denotes the amount of suppression observed in our assay. Subsequent
treatment recommendations take into account not only the patient’s assay results, but also
clinical signs, cyclosporine dose, and other immunosuppressive agents on board. This
approach truly allows for individual tailoring of drug therapy. Over the several years of
offering this assay, and consulting with veterinarians regarding results, our laboratory has
gradually developed the clinical experience needed to generate target levels of cytokine
expression that correlate with clinical outcome.
Development of the assay was not without its challenges. There are many
components that must fit together in order for the assay to function. As mentioned before,
we initially believed that a pre-treatment sample would need to be included for proper
analysis, however we quickly determined that collection of these samples was difficult
for the busy clinician, and therefore we adapted our analysis to fit their needs by
analyzing samples by their change in activation. Another issue encountered was activator
quality. All samples are activated upon arrival to the laboratory. Our analysis assesses the
change in activation within samples; therefore activators must be working appropriately
for an accurate interpretation to be made. Occasionally, unexpectedly poor activation of
both patients and control dogs could be traced back to poor activator quality. This issue
led to the initiation of quality control measures including running samples from a healthy
control dog as well as non-template control wells on every plate to ensure all components
of the assay, including activators, were working correctly.
While the development of our assay has assisted veterinarians with patient
management, there are still a number of questions yet to answer. The functionality of the
assay has yet to be explored for agents other than cyclosporine. Although the mechanism
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used in this assay is reported to be specific for cyclosporine and other calcineurin
inhibitors, such as tacrolimus, it may be worth exploring the assay in patients on other
immunosuppressants. Many patients receiving cyclosporine are also receiving concurrent
glucocorticoids and other immunosuppressive agents and, although the concurrent use of
other drugs is considered to have minimal impact on cytokine expression results in
human patients, an understanding of the impact of other drugs on the assay in dogs would
assist with interpretation of results. Similar assays could also be developed that are
specific for other immunosuppressive drug mechanisms of action and that quantify
different cytokines or other molecules. Our laboratory has to date focused on IL-2 and
IFN-γ, both of which are considered pro-inflammatory. Assays that also include antiinflammatory cytokines such as IL-10 may provide further information regarding the
relationship between cytokine expression and clinical outcome. In comparison to
cyclosporine other immunosuppressants are not as well studied in canine patients.
Despite this fact, these drugs are being increasingly substituted for cyclosporine in cases
of immune-mediated disease, most likely due to high cost associated with cyclosporine
use. It is very possible that these immunosuppressant drugs exhibit a degree of variability
in individual patients that is similar to cyclosporine, and that this variability simply has
yet to be discovered due to the lack of relevant pharmacokinetic and pharmacodynamic
studies in dogs. More research on the use of these other immunosuppressant drugs in
dogs will likely show similar individual-to-individual variation, and encourage the
development of drug-specific assays.
The assay developed in this thesis was specifically designed to be used in canine
patients, but cyclosporine is also used in feline cases of allergic dermatitis and as an
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immunosuppressant, especially after kidney transplants (which are more commonly
performed in cats). Although pharmacokinetic assays are available that measure whole
blood cyclosporine concentrations in cats, a pharmacodynamic assay has yet to be
developed in this species. Access to such an assay that assists with determining ideal
dosing protocols could help clinicians better manage their feline patients.
Analysis of samples from canine patients with different diseases has led us to
modify our recommendations. For certain localized diseases like atopy, typically low
suppression of IL-2 is observed, even though the patients’ skin disease is clinically well
controlled. We hypothesize that this is due to the fact that cyclosporine concentrates in
the skin and is able to keep disease under control due to a local effect, and therefore our
laboratory only recommends a change in dose if clinical signs are not adequately
controlled. A similar scenario has been encountered with dogs suffering from
inflammatory bowel disease (IBD). As with atopy cases, we suspect there is a local
immunosuppressive effect at the level of the gut in dogs with IBD receiving cyclosporine.
Since the assay measures the effects of cyclosporine on circulating T cells, it may not
give an accurate portrayal of local disease control, particularly in tissues where
cyclosporine is known to concentrate, such as the skin.
The greatest strength of our assay is that it is tailored to the individual patient.
Dosage adjustments in cyclosporine are recommended based on IL-2 expression, and are
therefore targeted in the specific mechanism of action of the drug. If the patient has
marked IL-2 suppression, but the disease is still not well controlled, it is recommended to
try an additional or alternative immunosuppressive agent, since cyclosporine is already
exhibiting its maximal effect. Additionally, marked IL-2 suppression is associated with a
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greater risk of secondary infection, and clinicians are advised to be vigilant for signs of
infection. In contrast, if the patient has low to moderate IL-2 suppression, and the disease
is not well controlled, increased cyclosporine dose rates are recommended. This assay is
specifically targeted to cyclosporine’s mechanism of action and indicates if cyclosporine
is at the correct dose for the patient. This may not necessarily mean that the immune
system is adequately suppressed in these individuals as other mechanisms could be at
play leading to immune-mediated disease. We suspect that a marked reduction in proinflammatory cytokines like IL-2 and IFN-γ would indicate that the immune response has
been decreased, but this effect has yet to be proved experimentally.
Use of this assay has also allowed us to identify dogs with altered cyclosporine
disposition. Using this assay, we were able to identify a dog with a profound reduction in
IL-2 expression despite a relatively low dose of cyclosporine. Subsequent investigation
into the case led to the discovery that the dog was heterozygous for the MDR1 gene
mutation. The MDR1 (or ABCB1) gene codes for the drug transporter P-glycoprotein, for
which cyclosporine is a known substrate and, amongst other functions, P-glycoprotein
serves as an efflux pump that pumps drugs such as cyclosporine out of lymphocytes.
Heterozygous dogs are known to exhibit reduced P-glycoprotein function, and therefore
we suspect that this led to increased intracellular levels of cyclosporine within T cells,
causing a high degree of suppression of IL-2 production despite a relatively low dose of
cyclosporine. This is just one example of the advantages of using a pharmacodynamicbased assay, since this effect may not have been noticed if only pharmacokinetic data was
used for monitoring.
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The overall objective for this dissertation research was to develop an assay that
provides valuable information for clinicians and their patients receiving cyclosporine
therapy. Initial results with clinical cases has been rewarding, and further investigation
and statistical analysis correlating case outcome to assay results is warranted. The work
in our laboratory also forges the way for the development of other assays for
individualized drug therapy in the canine patient.
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